<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput xmlns:ns2="local"><serviceExecutionTime>293</serviceExecutionTime><Trial id="184792"><TitleDisplay>The Role of the Gut Microbiota in the Systemic Immune Response During Human Endotoxemia</TitleDisplay><TitleOfficial>The Role of the Gut Microbiota in the Systemic Immune Response During Human Endotoxemia</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02127749</Identifier><Identifier type="Organisational Study">NL45198.018.13</Identifier><Identifier type="Other">NTR4549</Identifier><Identifier type="Other">NL45198.018.13 CCMO</Identifier><Identifier type="Trial Acronym">MISSION-2</Identifier></Identifiers><Indications><Indication id="40">Bacterial infection</Indication></Indications><BiomarkerNames><BiomarkerName id="125" role="Therapeutic effect marker" type="Cellular">Leukocyte count</BiomarkerName><BiomarkerName id="1925" role="Therapeutic effect marker" type="Cellular">Neutrophils</BiomarkerName><BiomarkerName id="36136" role="Therapeutic effect marker" type="Genomic;Proteomic">Cytokines</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>endotoxin</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>ciprofloxacin hydrochloride</Name><Drug id="44438">ciprofloxacin hydrochloride</Drug></Intervention><Intervention type="InterventionPrimary"><Name>endotoxin</Name></Intervention><Intervention type="InterventionPrimary"><Name>metronidazole</Name></Intervention><Intervention type="InterventionPrimary"><Name>vancomycin</Name><Drug id="44401">vancomycin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44401">vancomycin</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1040754">The Netherlands Organisation for Health Research and Development</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="26011">Academic Medical Center, University of Amsterdam</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44438">ciprofloxacin hydrochloride</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1040754">The Netherlands Organisation for Health Research and Development</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="26011">Academic Medical Center, University of Amsterdam</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="44401" type="Drug"><TargetEntity id="127147" type="siDrug">Vancomycin hydrochloride</TargetEntity></SourceEntity><SourceEntity id="44438" type="Drug"><TargetEntity id="90006" type="siDrug">Ciprofloxacin hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1040754" type="Company"><TargetEntity id="5035543155" type="organizationId">Zorgonderzoek Nederland</TargetEntity></SourceEntity><SourceEntity id="26011" type="Company"><TargetEntity id="5035524344" type="organizationId">Academic Medical Center</TargetEntity></SourceEntity><SourceEntity id="40" type="ciIndication"><TargetEntity id="A49.9" type="ICD10"></TargetEntity><TargetEntity id="10060945" type="MEDDRA"></TargetEntity><TargetEntity id="D001424" type="MeSH"></TargetEntity><TargetEntity id="-1693440076" type="omicsDisease"></TargetEntity><TargetEntity id="800" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="431" type="Action"><TargetEntity id="901" type="Mechanism">DNA Gyrase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="9320" type="Action"><TargetEntity id="1498" type="Mechanism">DNA Topoisomerase IV Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="26011">Academic Medical Center, University of Amsterdam</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1040754">The Netherlands Organisation for Health Research and Development</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="431">DNA gyrase inhibitor</Action><Action id="57003">Peptidoglycan recognition protein inhibitor</Action><Action id="9320">Topoisomerase IV inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="104">Bacterial cell wall synthesis inhibitor</Class><Class id="1479">RNA synthesis modulator</Class><Class id="15187">Systemic dermatological antibacterial product</Class><Class id="1594">Antibacterial</Class><Class id="3984">Bacterial nucleic acid synthesis inhibitor</Class></Class><Technologies><Technology id="66">Antibiotic</Technology><Technology id="586">Capsule formulation</Technology><Technology id="751">Film coating</Technology><Technology id="74">Glycoprotein</Technology><Technology id="743">Granule</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>16</PatientCountEnrollment><PatientCountEvaluable>13</PatientCountEvaluable><DateStart>2014-06-30T00:00:00Z</DateStart><DateEnd type="actual">2015-12-31T00:00:00Z</DateEnd><DateChangeLast>2019-05-03T06:35:38Z</DateChangeLast><DateAdded>2014-05-03T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Academic Medical Centre, Amsterdam</Affiliation><Name>W. J. Wiersinga, MD, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Healthy, as determined by a responsible physician, based on a medical evaluation including medical history, physical examination and laboratory tests &lt;/li&gt;&lt;li&gt;Male between 18 and 35 years of age&lt;/li&gt;&lt;li&gt;Capable of giving written informed consent&lt;/li&gt;&lt;li&gt;Chemistry panel including renal and liver function tests, without any clinically relevant abnormality as judged by the investigator&lt;/li&gt;&lt;li&gt;Normal defecation pattern&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Major illness in the past 3 months or any chronic medical illness&lt;/li&gt;&lt;li&gt;History of any type of malignancy&lt;/li&gt;&lt;li&gt;Past or current gastrointestinal disease&lt;/li&gt;&lt;li&gt;Known positive test for hepatitis C antibody, hepatitis B surface antigen or HIV antibody 1 or 2&lt;/li&gt;&lt;li&gt;Current or chronic history of liver disease&lt;/li&gt;&lt;li&gt;Subject uses tobacco products&lt;/li&gt;&lt;li&gt;History, within three years, of drug abuse&lt;/li&gt;&lt;li&gt;History of alcoholism&lt;/li&gt;&lt;li&gt;Any clinically relevant abnormality on the 12-lead ECG&lt;/li&gt;&lt;li&gt;The subject has received an investigational product within 3 months&lt;/li&gt;&lt;li&gt;Use of prescription or non-prescription drugs&lt;/li&gt;&lt;li&gt;Use of antibiotics within 12 months&lt;/li&gt;&lt;li&gt;Known allergy to antibiotics&lt;/li&gt;&lt;li&gt;Subject has difficultly in donating blood or accessibility of a vein in left or right arm&lt;/li&gt;&lt;li&gt;Subject has donated &gt; 350 ml of blood in last 3 months&lt;/li&gt;&lt;li&gt;Difficulty swallowing pills&lt;/li&gt;&lt;li&gt;Body mass index &gt; 28 kg/m2&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Cytokine production in blood</Description><Timeframe>Within 8 h after LPS administration</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Activation of coagulation Composition of gut microbiota</Description><Timeframe>At 0.5, 1, 1.5, 2, 3, 4, 6 and 8 h after LPS injection</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this randomized, between- and within-subject-controlled intervention study was to determine whether treatment with antibiotics, which harm the      gut flora, causes the immune system to be less effective and also to investigate the role of the gut microbiota in the systemic priming of immune effector cells during human endotoxemia.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In June 2016, results were published. Antibiotic treatment significantly reduced gut microbiota diversity in all subjects. Antibiotic-pretreated and control subjects did not report any difference in clinical parameters, neutrophil influx, cytokine production, coagulation activation and endothelial activation during endotoxemia. Further, during endotoxemia the antibiotic-treatment showed no impact on blood leukocyte responsiveness to various Toll-like receptor ligands and clinically relevant causative agents of sepsis (Streptococcus pneumoniae, Klebsiella pneumoniae, Escherichia coli) [&lt;ulink linkType="Reference" linkID="1956740"&gt;1956740&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2019, results were published. With a loss of diversity and drastic shifts in community composition, the short-term impact of broad-spectrum antibiotics on the gut microbiota was profound. There was a signficant reduction in abundance of bacterial taxa with important metabolic functions, such as the production of butyrate by the antibiotics. After 8 to 31?months, the microbiota showed a remarkable return towards baseline, but community composition often found to be remained altered from its initial state [&lt;ulink linkType="Reference" linkID="2147816"&gt;2147816&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;All subjects would receive lipopolysaccharide (endotoxin 2 ng/kg bodyweight)      iv to induce experimental endotoxemia. A total of eight subjects would be pretreated with      broad spectrum antibiotics (&lt;ulink linkType="Drug" linkID="44438"&gt;ciprofloxacin&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt;, metronidazole) for 7 days      (washout period of 36 h before endotoxemia), in order to deplete the gut microbiota.      Blood and feces would be sampled before, during and after endotoxemia.&lt;/para&gt;&lt;para&gt;Subjects would be randomized in to two treatment arms:&lt;br/&gt;Arm I: subjects  would not be pretreated with antibiotics and would receive 2 ng/kg endotoxin iv.&lt;br/&gt;Arm II: subjects would be pretreated with broad-spectrum antibiotics: &lt;ulink linkType="Drug" linkID="44401"&gt;vancomycin&lt;/ulink&gt; (500 mg tid), metronidazole (500 mg, tid), &lt;ulink linkType="Drug" linkID="44438"&gt;ciprofloxacin&lt;/ulink&gt; (500 mg, bid)  all together during 7 days and then receive 2 ng/kg endotoxin iv.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Subjects received either no treatment or broad-spectrum antibiotics (ciprofloxacin, vancomycin and metronidazole) for 7?days following which all subjects received intravenous lipopolysaccharide to induce a transient sepsis-like syndrome [&lt;ulink linkType="Reference" linkID="1956740"&gt;1956740&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2147816"&gt;2147816&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="421565">ciprofloxacin hydrochloride</Intervention><Treatments><Treatment><Dose>500 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="421566">endotoxin</Intervention><Treatments><Treatment><Dose>2 nanogram/kg</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="421564">metronidazole</Intervention><Treatments><Treatment><Dose>500 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="421528">vancomycin</Intervention><Treatments><Treatment><Dose>500 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Netherlands"><Sites><Site><Name>Academic Medical Centre</Name><Address1>Amsterdam</Address1><Address3>1105 AZ</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02127749</Identifier></Identifiers></Registry><Registry><Name id="1015">Netherlands Trial Registry (NTR)</Name><Identifiers><Identifier>NTR4549</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Chronic obstructive pulmonary disease" id="4390"><Endpoint>Assessment of Sputum</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Urinary tract infection" id="14189"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Urinary tract infection" id="14190">Assessment of Inflammatory/Immunological Markers</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Otitis media" id="14438"><Endpoint>Assessment of Immune Response</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Clostridium difficile infection" id="15398"><Endpoint>Assessment of Immune Response</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pneumonia" id="16593"><Endpoint>Assessment of Immune Response</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Diarrhea" id="25383"><Endpoint>Assessment of Immune Response</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Sepsis" id="43978"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Sepsis" id="16030">Assessment of cytokines</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Sepsis" id="15021"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion><Inclusion disease="Clostridium difficile infection" id="34710"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Clostridium difficile infection" id="14725">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Diarrhea" id="34716"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Diarrhea" id="22017">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Otitis media" id="34744"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Otitis media" id="13565">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pneumonia" id="34747"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Pneumonia" id="15589">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Sepsis" id="34752"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Sepsis" id="15025">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Urinary tract infection" id="34757"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Urinary tract infection" id="13480">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Chronic obstructive pulmonary disease" id="3076"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3085"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3093"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3194"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3239"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Urinary tract infection" id="10968"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Urinary tract infection" id="10969"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Urinary tract infection" id="10973"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Urinary tract infection" id="10974"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Urinary tract infection" id="10979"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Urinary tract infection" id="10983"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Urinary tract infection" id="10984"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Otitis media" id="11020"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Otitis media" id="11021"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Otitis media" id="11025"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Otitis media" id="11026"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Otitis media" id="11029"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Otitis media" id="11036"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Clostridium difficile infection" id="12144"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Clostridium difficile infection" id="12145"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Clostridium difficile infection" id="12146"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Clostridium difficile infection" id="12150"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Clostridium difficile infection" id="12151"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Clostridium difficile infection" id="12154"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Clostridium difficile infection" id="12158"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Sepsis" id="12410"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Sepsis" id="12411"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Sepsis" id="12416"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Sepsis" id="12422"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Pneumonia" id="12959"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Pneumonia" id="12961">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pneumonia" id="12963"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Pneumonia" id="12964"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Pneumonia" id="12968"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Pneumonia" id="12969"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Pneumonia" id="12973"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Pneumonia" id="12982"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Pneumonia" id="12983"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Diarrhea" id="19880"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Diarrhea" id="19884">Subjects with cardiac diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Diarrhea" id="19889"><Criterion>Subjects co-morbid with immunological disease/disorder</Criterion></Exclusion><Exclusion disease="Diarrhea" id="19893"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Diarrhea" id="19917"><Criterion>Subjects with Abnormal/Unacceptable Clinical Assessments</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="20272"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="20274"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Diarrhea" id="25867"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Diarrhea" id="19891">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Diarrhea" id="26047"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Diarrhea" id="19882">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2015-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2014-04-28T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-05-03T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2014-06-26T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2016-01-06T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-08-30T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="updated"><Date>2019-05-03T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change><Change type="updated"><Date>2019-05-03T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="217101"><TitleDisplay>Safety and Efficacy Study of NUC-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer</TitleDisplay><TitleOfficial>Phase Ib, Open-Label Study to Assess the Safety, Pharmacokinetics and Clinical Activity of NUC-1031 Given on Days 1 and 8 With Carboplatin on Day 1, q3-Weekly for Six Cycles in Participants With Recurrent Ovarian Cancer</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02303912</Identifier><Identifier type="Secondary Organisational">2014-002006-21</Identifier><Identifier type="Organisational Study">PRO-002</Identifier><Identifier type="Other">UKCRN 17422</Identifier><Identifier type="Trial Acronym">ProGem2</Identifier></Identifiers><Indications><Indication id="2243">Fallopian tube cancer</Indication><Indication id="3083">Peritoneal tumor</Indication><Indication id="799">Ovary tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="71" role="Therapeutic effect marker" type="Genomic;Proteomic">CA-125 antigen</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>gemcitabine prodrug (ProTide, cancer), NuCana Biomed</Name><Drug id="64717">gemcitabine prodrug (ProTide, cancer), NuCana Biomed</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>gemcitabine prodrug (ProTide, cancer), NuCana Biomed + carboplatin</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>carboplatin</Name><Drug id="44383">carboplatin</Drug></Intervention><Intervention type="InterventionPrimary"><Name>gemcitabine prodrug (ProTide, cancer), NuCana Biomed</Name><Drug id="64717">gemcitabine prodrug (ProTide, cancer), NuCana Biomed</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44383">carboplatin</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1090647">Imperial College Healthcare NHS trust</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="64717">gemcitabine prodrug (ProTide, cancer), NuCana Biomed</Drug><IndicationsPioneer><Indication id="2243">Fallopian tube cancer</Indication><Indication id="3083">Peritoneal tumor</Indication></IndicationsPioneer><Companies><Company><Company id="1090647">Imperial College Healthcare NHS trust</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="64717">gemcitabine prodrug (ProTide, cancer), NuCana Biomed</Drug><IndicationsPioneer><Indication id="2243">Fallopian tube cancer</Indication><Indication id="3083">Peritoneal tumor</Indication></IndicationsPioneer><Companies><Company><Company id="1090647">Imperial College Healthcare NHS trust</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="44383" type="Drug"><TargetEntity id="125568" type="siDrug">Carboplatin</TargetEntity></SourceEntity><SourceEntity id="64717" type="Drug"><TargetEntity id="417580" type="siDrug">Acelarin</TargetEntity><TargetEntity id="417580" type="siDrug">Acelarin</TargetEntity></SourceEntity><SourceEntity id="1090647" type="Company"><TargetEntity id="5000063490" type="organizationId">Imperial College Healthcare NHS Trust</TargetEntity></SourceEntity><SourceEntity id="2243" type="ciIndication"><TargetEntity id="C57.0" type="ICD10"></TargetEntity><TargetEntity id="10016180" type="MEDDRA"></TargetEntity><TargetEntity id="D005185" type="MeSH"></TargetEntity><TargetEntity id="-33569282" type="omicsDisease"></TargetEntity><TargetEntity id="600" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3083" type="ciIndication"><TargetEntity id="C48" type="ICD10"></TargetEntity><TargetEntity id="10061344" type="MEDDRA"></TargetEntity><TargetEntity id="D010534" type="MeSH"></TargetEntity><TargetEntity id="-745704479" type="omicsDisease"></TargetEntity><TargetEntity id="633" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="799" type="ciIndication"><TargetEntity id="C56" type="ICD10"></TargetEntity><TargetEntity id="10033128" type="MEDDRA"></TargetEntity><TargetEntity id="D010051" type="MeSH"></TargetEntity><TargetEntity id="-1370909262" type="omicsDisease"></TargetEntity><TargetEntity id="626" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1090647">Imperial College Healthcare NHS trust</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="140">DNA synthesis inhibitor</Class><Class id="1545">Anticancer</Class><Class id="1569">Anticancer antimetabolite</Class><Class id="50">Anticancer alkylating agent</Class></Class><Technologies><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="102">Nucleotide and derivatives</Technology><Technology id="1652">Prodrug</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>25</PatientCountEnrollment><PatientCountEvaluable>22</PatientCountEvaluable><DateStart>2014-11-30T00:00:00Z</DateStart><DateEnd type="actual">2017-01-23T00:00:00Z</DateEnd><DateChangeLast>2019-05-10T02:07:24Z</DateChangeLast><DateAdded>2014-12-12T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Imperial College Healthcare NHS Trust</Affiliation><Email>s.blagden@imperial.ac.uk</Email><Name>Sarah Blagden</Name><Phone>00442033138370</Phone></Contact><Contact type="Public contact"><Email>ajithkumar.sukumaran@imperial.nhs.uk</Email><Name>Ajithkumar Sukumaran</Name><Phone>00442033131703</Phone></Contact><Contact type="Scientific contact"><Affiliation>University of Oxford</Affiliation><Name>Sarah Blagden, MBBS, MRCP</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Provision of signed written informed consent&lt;/li&gt;&lt;li&gt;Original diagnosis and/or histological confirmation of relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer&lt;/li&gt;&lt;li&gt;Relapse&amp;lt;/= 24 months from completion of platinum (&lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; or cisplatin) or platinum-containing regimen&lt;/li&gt;&lt;li&gt;Age &gt;/= 18 years&lt;/li&gt;&lt;li&gt;Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2&lt;/li&gt;&lt;li&gt;Measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1, January 2009 and/or evaluable disease (evaluable: cytologically or radiologically detectable disease such as ascites, peritoneal deposits, or lesions which do not fulfill RECIST criteria version 1.1 for measurable disease). Participants for whom disease and response to therapy can be monitored by serum cancer antigen-125 (CA-125) levels will also be eligible&lt;/li&gt;&lt;li&gt;Adequate bone marrow function as defined by:&lt;ul&gt;&lt;li&gt;White blood xells of &gt;/= 3  x 10(9)/l&lt;/li&gt;&lt;li&gt;Absolute neutrophil count (ANC) of &gt;/= 2.0 x 10(9)/l&lt;/li&gt;&lt;li&gt;Platelet count of &gt;/= 100.0 x 10(9)/l&lt;/li&gt;&lt;li&gt;Hemoglobin of &gt;/= 9 g/dl&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Adequate liver function, as determined by:&lt;ul&gt;&lt;li&gt;Serum total bilirubin&amp;lt;/= 1.5 x upper limit of normal (ULN)&lt;/li&gt;&lt;li&gt;Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)&amp;lt;/= 2.5 x ULN&lt;/li&gt;&lt;li&gt;Albumin &gt;/= 30 g/l&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Adequate renal function assessed as glomerular filtration rate (GFR) &gt;/= 60 ml/min using Cr51-ethylenediaminetetraacetic acid (EDTA) method&lt;/li&gt;&lt;li&gt;Ability to comply with protocol requirements&lt;/li&gt;&lt;li&gt;Participants must be postmenopausal (12 months of amenorrhea), surgically sterile or they must agree to use a physical method of contraception.  Oral or injectable contraceptive agents cannot be the sole method of contraception.  Participants of child-bearing potential must have a negative serum pregnancy test within 7 days prior to the first study drug administration&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;History of allergic reactions attributed to previous gemcitabine treatment&lt;/li&gt;&lt;li&gt;Previous treatment with&lt;ulink linkType="Drug" linkID="64717"&gt;NUC-1031&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;History of allergic reactions attributed to previous&lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; treatment&lt;/li&gt;&lt;li&gt;Symptomatic central nervous system (CNS) or leptomeningeal metastases&lt;/li&gt;&lt;li&gt;Prior chemotherapy, radiotherapy (other than short cycle of palliative radiotherapy for bone pain), or immunotherapy within 28 days of first receipt of study drug (within 6 weeks for nitrosoureas and mitomycin C).  Hormone therapy within 14 days of first receipt of study drug&lt;/li&gt;&lt;li&gt;Prior toxicities from chemotherapy or radiotherapy which have not regressed to grade&amp;lt;/= 1 severity (National Cancer Institute-Common Terminology Criteria for Adverse Events, [NCI-CTCAE] version 4.03) except for neuropathy and alopecia&lt;/li&gt;&lt;li&gt;Another active cancer (excluding basal cell carcinoma) within the last three years&lt;/li&gt;&lt;li&gt;Participants with uncontrolled concomitant illness or active infection requiring iv antibiotics&lt;/li&gt;&lt;li&gt;Participants with serious illnesses, medical conditions, or other medical history, including laboratory results, which, in the investigator's opinion, would be likely to interfere with a their participation in the study, or with the interpretation of the results&lt;/li&gt;&lt;li&gt;Known Human Immunodeficiency Virus (HIV) or known active hepatitis B or C&lt;/li&gt;&lt;li&gt;Any condition (eg, known or suspected poor compliance, psychological instability, geographical location, etc) that, in the judgment of the investigator, may affect the participant's ability to sign the informed consent and undergo study procedures&lt;/li&gt;&lt;li&gt;Currently pregnant, lactating or breastfeeding&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>To determine the recommended phase II dose (RP2D) of NUC-1031 and carboplatin when administered in combination</Description><Timeframe>One year</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>To evaluate overall best response, utilising the evaluation criteria determined by the Gynecologic Cancer Intergroup (GCIG), combining the change in CA-125 from baseline with RECIST version 1.1 assessment</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>To evaluate the clinical benefit rate (CBR) of NUC-1031 administered in combination with carboplatin in participants with recurrent ovarian cancer</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>To evaluate the objective response rate (ORR) of NUC-1031 administered in combination with carboplatin in participants with recurrent ovarian cancer</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>To evaluate the progression-free survival (PFS) of participants with recurrent ovarian cancer treated with NUC-1031 in combination with carboplatin</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>To evaluate the safety and tolerability of NUC-1031 administered in combination with carboplatin measured by adverse events (AE) and changes from baseline in vital signs, clinical laboratory parameters, and electrocardiography (ECG) assessments</Description><Timeframe>One year</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In May 2015, results were published.  Treatment with NUC-1031 was well tolerated with no unexpected adverse events [&lt;ulink linkType="Reference" linkID="1664955"&gt;1664955&lt;/ulink&gt;]. Similar results were presented in June 2016 [&lt;ulink linkType="Reference" linkID="1769900"&gt;1769900&lt;/ulink&gt;].   In September 2017, similar results were presented [&lt;ulink linkType="Reference" linkID="1960411"&gt;1960411&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2017, further  results were presented.  A total of four patients reported DLTs like two events of grade 4 thrombocytopenia (NUC-1031 625 mg/m2 + 750 mg/m2 + carboplatin AUC 4), three events of grade 3 fatigue (NUC-1031 625 mg/m2 + carboplatin AUC 4), and one event of grade 4 neutropaenia (NUC-1031 750 mg/m2 + carboplatin AUC 4). In platinum partially sensitive or sensitive patients (n = 7), thrombocytopaenia was not reported. Common grade 3/4 TEAEs like neutropenia, leucopenia, thrombocytopenia, fatigue, anemia and lymphopenia were reported by 52, 28, 32, 16, 12 and 12% of patients in total population, respectively; 42, 8, 33, 0, 17 and 0% of patients in 500 mg/m2 NUC-1031 + AUC5 carboplatin treated patients (n = 12), respectively; 50, 17, 33, 50, 17 and 0% of patients in 625 mg/m2 NUC-1031 +AUC4 carboplatin treated patients (n = 6), respectively; 67, 67, 33, 17, 0 and 50% of patients in 750 mg/m2 NUC-1031 + AUC4 carboplatin treated patients (n = 6), respectively; and 100, 100, 0, 0, 0 and 0% of patients in 750 mg/m2 NUC-1031 + AUC5 carboplatin treated patients (n = 1), respectively [&lt;ulink linkType="Reference" linkID="1960411"&gt;1960411&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a first-in-human experimental treatment of investigational medicine, &lt;ulink linkType="Drug" linkID="64717"&gt;NUC-1031&lt;/ulink&gt;, used      in combination with a standard cancer medicine, &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt;, to treat ovarian cancer which      reappear after standard cancer treatment. The aim of the trial was to determine safety,      effectiveness, and clinical activity of this combination treatment.&lt;/para&gt;&lt;para&gt;The aim of the study was to      investigate whether adding &lt;ulink linkType="Drug" linkID="64717"&gt;NUC-1031&lt;/ulink&gt; to &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; could   improve the benefits of chemotherapy. Other purposes were to find out whether &lt;ulink linkType="Drug" linkID="64717"&gt;NUC-1031&lt;/ulink&gt; was safe to give with &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt;, to identify the correct dose of &lt;ulink linkType="Drug" linkID="64717"&gt;NUC-1031&lt;/ulink&gt; when given with &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; and establish how effective the combination was at treating ovarian cancer. This study was also designed to enable us to find out whether &lt;ulink linkType="Drug" linkID="64717"&gt;NUC-1031&lt;/ulink&gt; would add further benefit, over and above that achieved by &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; alone, when treating ovarian cancer. &lt;br/&gt;&lt;br/&gt; &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In May 2015, results were published.  Treatment with  NUC-1031 achieved an exceptional 93% disease control rate in patients with advanced progressive gynecological tumours relapsed or refractory to all standard therapies. A total of  14 patients 14% achieved a partial response and 79% stable disease, for an overall disease control rate of 93%. However, this disease control showed durability with progression free survival of 8.2 months ongoing [&lt;ulink linkType="Reference" linkID="1664955"&gt;1664955&lt;/ulink&gt;].  Similar results were presented in June 2016 [&lt;ulink linkType="Reference" linkID="1769900"&gt;1769900&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, positive interim results of 22 patients were presented.   Out of 22, 20 patients were evaluated for significant clinical activity which was  achieved in  with an overall response rate of 30%, including 5% complete response, 25% partial responses and 65% with stable disease. The overall disease control rate was 95%, which was durable, with a progression free survival already at 6.6 months and ongoing [&lt;ulink linkType="Reference" linkID="1769900"&gt;1769900&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2017, results were presented. Response was evaluated in a total of 23 patients who received &gt;/= 1 cycle of treatment. In pharmacokinetic studies, NUC-1031 treatment in combination with carboplatin exhibited a rapid generation of very high levels of intracellular active anti-cancer metabolite gemcitabine triphosphate (dFdCTP) with Cmax of 14.0 microM/mg, tissue/protein of 500 mmg/m2 and Tmax of 30 min; and these levels were maintained for 24 h.  [&lt;ulink linkType="Reference" linkID="1960411"&gt;1960411&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2017, results were presented. NUC-1031 in combination with carboplatin achieved 96% disease control rate and 39% respeonse rate in 23 evaluable patients with recurrent cancer. In all patients and evaluable patient population (n = 25 and 23), complete response was achieved by each 4% of patients; partial response (PR) was achieved by 32 and 35% of patients, respectively; objective response rate (ORR) was 36 and 39%, respectively; stable disease (SD) was observed in 52 and 57% of patients, respectively; and clinical benefit rate was 89 and 96%, respectively. The duration of SD was 7.4 months. The progression-free survival (PFS) was 7.4 months. PR was achieved in three patients who were resistant to first platinum-containing regimen (n = 6). In platinum refractory/resistant and platinum partially sensitive/sensitive patients (n = 17 and 6, respectively), the ORR was 29 and 67%, respectively. Also, PR was achieved in a patient had previously progressed on olaparib; with stage 9% reduction in tumor volume and a PFS of 7.2 months. The recommended phase II dose of NUC-1031 was 500 mg/m2 NUC-1031 (on days 1 and 8) + AUC5 carboplatin (day 1, q21d) [&lt;ulink linkType="Reference" linkID="1983287"&gt;1983287&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive &lt;ulink linkType="Drug" linkID="64717"&gt;NUC-1031&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; combination  for six cycles; each cycle of 3 weeks long. Dose escalation would  be done using 3 + 3 dose escalation design. On day 1 of week 1 of each cycle,      selected study patients would receive one dose of  &lt;ulink linkType="Drug" linkID="64717"&gt;NUC-1031&lt;/ulink&gt;  iv injection and &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt;      iv infusion. Following this, the study patients would receive a second dose of &lt;ulink linkType="Drug" linkID="64717"&gt;NUC-1031&lt;/ulink&gt;      iv injection alone on day 1 of week 2 (day 8). This schedule would be repeated every 3 weeks for      six cycles. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients  received NUC-1031 [&lt;ulink linkType="Reference" linkID="1664955"&gt;1664955&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Patients (n = 25) received NUC-1031 (500, 625 and 750 mg/m2) on days 1 and 8 + carboplatin (AUC 4 or 5) on day 1, q3w for &amp;lt;/= 6 cycles [&lt;ulink linkType="Reference" linkID="1960411"&gt;1960411&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>gemcitabine prodrug (ProTide, cancer), NuCana Biomed + carboplatin</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="17">Anemia</Indication></AdverseEvent><AdverseEvent><Indication id="1991">Neutropenia</Indication></AdverseEvent><AdverseEvent><Indication id="1992">Lymphocytopenia</Indication></AdverseEvent><AdverseEvent><Indication id="324">Thrombocytopenia</Indication></AdverseEvent><AdverseEvent><Indication id="680">Leukopenia</Indication></AdverseEvent><AdverseEvent><Indication id="829">Fatigue</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="555978">gemcitabine prodrug (ProTide, cancer), NuCana Biomed</Intervention><Treatments><Treatment><Dose>500 milligram/m2</Dose><Route>Intravenous</Route></Treatment><Treatment><Dose>625 milligram/m2</Dose><Route>Intravenous</Route></Treatment><Treatment><Dose>750 milligram/m2</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Name>Garry Weston Cancer Centre, Hammersmith Hospital</Name><Address1>London</Address1><Address3>W12 0HS</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Ovary tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="7879">Subjects with Ovarian Epithelial Tumor</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7894">Subjects with Recurrent or Persistent Ovarian Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7895">Platinum-Resistant/Refractory Ovarian Cancer Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7902">Ovarian Cancer Subjects with CA-125 Expression</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02303912</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2014-002006-21</Identifier></Identifiers></Registry><Registry><Name id="1023">UK Clinical Research Network (UKCRN)</Name><Identifiers><Identifier>UKCRN 17422</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Ovary tumor" id="10938"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Ovary tumor" id="10830"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Ovary tumor" id="10838"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Ovary tumor" id="10839">Assessment of overall/objective response rate(ORR)</SubEndpoint><SubEndpoint disease="Ovary tumor" id="10840">Assessment of Clinical Benefit Rate (CBR)</SubEndpoint><SubEndpoint disease="Ovary tumor" id="10844">Assessment of CA-125/serological response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Ovary tumor" id="10886"><Endpoint>Assessment of Vital Signs</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Ovary tumor" id="10888"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Ovary tumor" id="10895">Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Ovary tumor" id="10900"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Ovary tumor" id="10902">Assessment of adverse events as graded by CTCAE/CTC</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Ovary tumor" id="10926"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Ovary tumor" id="10939"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Ovary tumor" id="8204"><Criterion>Subjects with Ovarian Epithelial Tumor</Criterion></Inclusion><Inclusion disease="Ovary tumor" id="8219"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Ovary tumor" id="8227"><Criterion>Ovarian Cancer Subjects with CA-125 Expression</Criterion></Inclusion><Inclusion disease="Ovary tumor" id="8248"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8250">Subjects with disease measurable by imaging techniques</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="8262"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8263">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Ovary tumor" id="8264">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Ovary tumor" id="8265">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="8281"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8282">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Ovary tumor" id="8283">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="8288"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8302">Women of non-childbearing potential/surgically sterile women/Postmenopausal women</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="33605"><Criterion>Subjects with Treatment Resistant Disease</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8220">Platinum-Resistant/Refractory Ovarian Cancer Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="34009"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8284">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="34120"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8300">Non Pregnant/Non lactating women</SubCriterion><SubCriterion disease="Ovary tumor" id="8301">Subjects with adequate contraception</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="34426"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8295">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Ovary tumor" id="34899"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="8297">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Ovary tumor" id="9809"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Ovary tumor" id="9811"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="9812">Subjects co-morbid with HIV infection</SubCriterion><SubCriterion disease="Ovary tumor" id="9813">Subjects co-morbid with hepatitis virus infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ovary tumor" id="9820"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="9863">Subjects failing to meet protocol specified laboratory criteria</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ovary tumor" id="9829"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="9830">Subjects with hypersensitivity/contraindication to chemotherapeutic agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ovary tumor" id="9837"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="9838">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Ovary tumor" id="9841">Subjects with history of/scheduled to receive hormone therapy</SubCriterion><SubCriterion disease="Ovary tumor" id="9842">Subjects with history of radiotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ovary tumor" id="9846"><Criterion>Subjects with Therapy Associated Toxicity</Criterion></Exclusion><Exclusion disease="Ovary tumor" id="9847"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="9850">Subjects with medical condition interfering with the study protocol</SubCriterion><SubCriterion disease="Ovary tumor" id="12430">Subjects not recovered from prior therapy/therapies and/their toxic/adverse events</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ovary tumor" id="25625"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="9848">Subjects with inability/unwillingness to provide informed consent</SubCriterion><SubCriterion disease="Ovary tumor" id="9851">Subjects not suitable to participate as per investigator's discretion</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ovary tumor" id="25759"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="9857">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ovary tumor" id="26841"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="9840">Subjects with history of biologic therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Ovary tumor" id="27925"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Ovary tumor" id="9849">Subjects with inability/unwillingness to comply with the protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2017-01-23T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2014-10-10T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-12-12T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2015-08-01T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2015-08-01T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="updated"><Date>2015-10-09T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="Added"><Date>2017-11-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-11-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-11-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-11-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-11-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-11-20T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="updated"><Date>2019-04-11T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="288337"><TitleDisplay>Use of Eye Exercises to Improve Vision</TitleDisplay><TitleOfficial>Novel Way to Strengthen Eye Muscle and Enhance Peripheral Vision</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03054597</Identifier><Identifier type="Organisational Study">ACSEF2012JB</Identifier></Identifiers><Indications><Indication id="239">Ocular disease</Indication></Indications><BiomarkerNames><BiomarkerName id="19714" role="Therapeutic effect marker" type="Physiological">Muscle strength</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>circular light motion exercise</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>diagonal light motion exercise</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>peripheral light motion exercise</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="29856" type="Company"><TargetEntity id="5035440596" type="organizationId">UC Davis (Division)</TargetEntity></SourceEntity><SourceEntity id="239" type="ciIndication"><TargetEntity id="10015916" type="MEDDRA"></TargetEntity><TargetEntity id="D005128" type="MeSH"></TargetEntity><TargetEntity id="-2056365523" type="omicsDisease"></TargetEntity><TargetEntity id="754" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="29856">University of California Davis</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>19</PatientCountEnrollment><DateStart>2012-02-29T00:00:00Z</DateStart><DateEnd type="actual">2012-04-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-15T22:21:15Z</DateChangeLast><DateAdded>2017-02-18T00:00:00Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Able to read English&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Cannot be colorblind&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Eye muscle endurance: the time spent exercising prior to eye strain</Description><Timeframe>2 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Peripheral reading range: the lateral degrees at which the test subject could read the letters on a card</Description><Timeframe>2 weeks</Timeframe></Measure><Measure><Description>Peripheral vision: the lateral degrees at which the test subject could see a blank card</Description><Timeframe>2 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of this experiment was to see      if a specific eye exercises technique can increase eye muscle strength and improve the peripheral      vision range of children and adults.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Experiments would be conducted by asking the test subjects (children and adults) to follow,      with their eyes, a set of blinking LED lights on three vision exercise devices. These LED lights      would be laid in circular or diagonal configurations, and programed using a microcontroller to      blink or 'move' in certain directions and at certain speeds.&lt;br/&gt;An endurance score, measured as      total time that the test subject completed while following the blinking LED lights before      his/her eyes became tired, would be recorded. Nineteen test subjects aged 12 to 81 would be asked to      exercise their eyes four times over 2 weeks using the devices for as long as they could      until subjects experienced mild eye fatigue. Endurance scores, peripheral vision, and peripheral      reading ranges would be assessed before and after the training sessions.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Hopkins Junior High School</Name><Address1>Fremont</Address1><Address2>California</Address2><Address3>94539</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other ocular disease</Disease><PatientSegments><PatientSegment><PatientSegment id="16684">Others</PatientSegment><SubSegments><SubSegment id="18791">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03054597</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other ocular disease" id="43555"><Endpoint>Clinical Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other ocular disease" id="43440"><Endpoint>Assessment of Visual Function</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Other ocular disease" id="43240"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other ocular disease" id="32980"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other ocular disease" id="34644"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Other ocular disease" id="32981">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other ocular disease" id="24993"><Criterion>Subjects co-morbid with Ocular Disorders/Diseases</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2012-04-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-02-13T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-02-18T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="344129"><TitleDisplay>Videogame Assisted Pulmonary Rehabilitation In Patients With Chronic Obstructive Pulmonary Disease</TitleDisplay><TitleOfficial>Videogame Assisted Pulmonary Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03567772</Identifier><Identifier type="Organisational Study">USEBELASMARET</Identifier></Identifiers><Indications><Indication id="1185">Chronic obstructive pulmonary disease</Indication></Indications><BiomarkerNames><BiomarkerName id="147" role="Therapeutic effect marker" type="Physiological">Six-minute walk distance</BiomarkerName><BiomarkerName id="1904" role="Therapeutic effect marker" type="Physiological">Heart rate</BiomarkerName><BiomarkerName id="1913" role="Therapeutic effect marker" type="Physiological">Arterial oxygen saturation</BiomarkerName><BiomarkerName id="2095" role="Therapeutic effect marker" type="Physiological">Mean arterial pressure</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Pulmonary rehabilitation program</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Wiifit Nintendo video game program</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>Pulmonary rehabilitation program with ergometer cycle</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1166834" type="Company"><TargetEntity id="5064614550" type="organizationId">Universitas Sebelas Maret</TargetEntity></SourceEntity><SourceEntity id="1185" type="ciIndication"><TargetEntity id="10009033" type="MEDDRA"></TargetEntity><TargetEntity id="D029424" type="MeSH"></TargetEntity><TargetEntity id="-459670493" type="omicsDisease"></TargetEntity><TargetEntity id="277" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1166834">Universitas Sebelas Maret</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>20</PatientCountEnrollment><DateStart>2014-02-01T00:00:00Z</DateStart><DateEnd type="actual">2014-07-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-13T15:47:27Z</DateChangeLast><DateAdded>2018-06-27T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Pulmonary Department of Medical faculty Universitas Sebelas Maret, Surakarta Indonesia</Affiliation><Name>Ana Rima, Dr</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;COPD based on GOLD guidelines&lt;/li&gt;&lt;li&gt;COPD stable (no exacerbation in the  4 weeks prior to study)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Refusal to participate&lt;/li&gt;&lt;li&gt;Participation in a PRP during the previous 6 months&lt;/li&gt;&lt;li&gt;Severe concomitant comorbidities such as ischaemic cardiac disease, chronic heart failure, orthopaedic and/or neuromuscular diseases interfering with their ability to walk&lt;/li&gt;&lt;li&gt;Dropout criteria:&lt;ul&gt;&lt;li&gt;Acute exacerbation&lt;/li&gt;&lt;li&gt;Inability/unwillingness to follow the research program&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Exercise tolerance: before and after the pulmonary rehabilitation program the exercise tolerance is measured by Six minute walking distance test (6MWT). Participants have to walk as far as possible for 6 minutes. Participants will walk back and forth in the hallway. Six minutes is a long time to walk, participants are permitted to slow down, to stop and to rest as necessary. The scale will be in meter (m). Higher values represent a better outcome</Description><Timeframe>6 weeks</Timeframe></Measure><Measure><Description>Health related quality of life: St George's Respiratory Questionnaire (SGRQ): before and after the pulmonary rehabilitation program, health related quality of life is measured by St George's Respiratory Questionnaire (SGRQ). Three component scores are calculated: symptoms; activity; impacts. One total score is also calculated. Each questionnaire response has a unique empirically derrived weight. The lowest possible weight is zero and the highest is 100. Higher values represent a worse outcome</Description><Timeframe>6 weeks</Timeframe></Measure><Measure><Description>Dyspnea: before and after the pulmonary rehabilitation program the dyspnoea was assessed by means of the Baseline (BDI) and Transitional (TDI) dyspnoea index. Three component scores are calculated: functional impairment; magnitude of task; magnitude of effort. The lowest possible score is -3 and the highest score is +3. Higher values represent a better outcome</Description><Timeframe>6 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study was to      evaluate the effectiveness of Wii fit Nintendo as a pulmonary rehabilitation programs (PRP)  tool in chronic obstructive pulmonary disease (COPD) patients with a      randomized, controlled trial methods.&lt;br/&gt;The study hypothesis was therefore to observe a 30 m post-PRP change in both groups. To obtain a 90% study power and an alpha error &amp;lt; 5%, a minimum sample size of 12 patients completing the study was required in each group.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In this randomized, clinical trial (RCT) patients would be assigned to two groups: the      experimental group (EG) would be receiving a hospital based outpatient PRP and Wii Fit videogame      program, the control group (CG) would be receiving only a standard hospital based outpatient PRP.      Researchers would be evaluating results and patients would  be  not blind to treatment. Patients maintained      their usual drug medication according to accepted guidelines.&lt;br/&gt;Patients of both groups would be receiving for  6 weeks three weekly 30 min sessions of supervised      standard cycle exercise training at outpatient clinics under the supervision of doctors and      nurses. The EG would be performing  Wii fit program (yoga, strength training, aerobic exercise) twice a week for 6 weeks, the CG would be performing cycle ergometer twice a week for 6 weeks. Oxygen pulse oximetry (SpO2), arterial blood pressure, heart rate (HR) and dyspnoea      (by a ten point modified Borg scale) would be monitored. In addition to each session of exercise training, patients of EG performed also 30 min       session of supervised video-game assisted program in a dedicated room equipped with Wii      Nintendo, balance board, and flatscreen television. Patients would played three different games per      session:&lt;br/&gt;Yoga with 'deep breathing' and 'half moon' : patients would be performing technique of breathing           and held a particular pose or series of poses for 10 min.&lt;br/&gt;Torso twist: a strength training exercise in which patients would be performing a number of           repetitions of the selected exercise.&lt;br/&gt;Aerobic exercises 'free run: the patient runs in place while keeping the connected Wii           Remote in his/her pocket, which acts as a pseudo-pedometer.&lt;br/&gt;The primary outcome measure was the 6 min walking test (6MWT). Results  would be shown as mean (standard deviation: SD)      for continuous and as numbers (percentage frequency) for discrete variables. To determine the      sample size, an earlier study showed a post-program 70.4 (18.3) meter mean increase in 6MWT. To obtain this result  investigators  would be estimating  an allocation sample size of 40 patients, considering a 20% drop out rate. Unpaired t test, Kruskall-Wallis H test, and X2 analysis for dichotomous variables would be used when appropriate for comparison between groups to test any baseline difference. The two-way repeated measures ANOVA was carried out to compare the improvements of both groups. Chi-square test was used to compare continuous and categorical variables. A p-value &amp;lt; 0.05 was considered as statistically significant. Analysis would be performed using a specific package (SPSS for windows latest version, Chicago, Illinois, USA).&lt;/para&gt;&lt;para&gt;Patients would receive Pulmonary rehabilitation program using video games exercise from Nintendo or pulmonary rehabilitation program with ergometer cycle.&lt;/para&gt;&lt;para&gt;The study hypothesis was therefore to observe a 30 m post-PRP change in both groups. To      obtain a 90% study power and an alpha error less than 5%, a minimum sample size of 12      patients completing the study was required in each group.&lt;/para&gt;&lt;para&gt;To obtain this result we estimated an allocation sample size of 40 patients, considering a      20% drop out rate. Unpaired t test, Kruskall-Wallis H test, and X2 analyses for dichotomous variables were used      when appropriate for comparison between groups to test any baseline difference. The two-way repeated measures ANOVA was carried out to compare the improvements of both      groups.&lt;/para&gt;&lt;para&gt;Chi-square test was used to compare continuous and categorical variables. A p value less than      0.05 was considered as statistically sig-nificant. Analyses were performed using a specific      package (SPSS for Windows latest version, Chicago, Illinois, USA).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Indonesia"><Sites><Site><Name>Pulmonary department of medical faculty Universitas Sebelas Maret</Name><Address1>Surakarta</Address1><Address2>Central Java</Address2><Address3>57126</Address3><CountrySubDivision>Central Java</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Chronic obstructive pulmonary disease</Disease><PatientSegments><PatientSegment><PatientSegment id="556">Subjects with Stable COPD</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03567772</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Chronic obstructive pulmonary disease" id="4432"><Endpoint>Assessment of Dyspnea</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Chronic obstructive pulmonary disease" id="4437"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4449">Changes in St Georges Respiratory Questionnaire (SGRQ)</SubEndpoint><SubEndpoint disease="Chronic obstructive pulmonary disease" id="29218">Assessment by Health Related Quality of Life (HRQOL)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Chronic obstructive pulmonary disease" id="4501"><Endpoint>Assessment of Exercise Capacity/Tolerance</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4502">Six-minute walk test (6MWT)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4404"><Endpoint>Assessment of BODE Index for COPD</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4413"><Endpoint>Assessments of Airway Status/Obstruction</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4418"><Endpoint>Assessment of Disease Progression</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4421">Prevalence of airflow obstruction</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4432"><Endpoint>Assessment of Dyspnea</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4436">Improvement in subjective dyspnea score</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4437"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4442">Dyspnea assessed by Medical Research Council Dyspnea Scale (MRCS)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="4501"><Endpoint>Assessment of Exercise Capacity/Tolerance</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4408">Assessment of exercise capacity</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Chronic obstructive pulmonary disease" id="44168"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4405">Assessment of BMI</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Chronic obstructive pulmonary disease" id="4336"><Endpoint>Assessment of Blood Gas Analysis/Alveolar Diffusion Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4344">Assessment of oxygen saturation (SaO2/SpO2)</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Chronic obstructive pulmonary disease" id="4432"><Endpoint>Assessment of Dyspnea</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4441">Dyspnea assessed by Borg Scale/Modified Borg Scale (MBS)</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Chronic obstructive pulmonary disease" id="4550"><Endpoint>Assessment of Vital Signs</Endpoint><SubEndpoints><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4551">Blood pressure assessment</SubEndpoint><SubEndpoint disease="Chronic obstructive pulmonary disease" id="4552">Assessment of heart rate</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Chronic obstructive pulmonary disease" id="2060"><Criterion>Subjects with Diagnosis of COPD</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="2064">Subjects with stable COPD</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Chronic obstructive pulmonary disease" id="34771"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Chronic obstructive pulmonary disease" id="3044"><Criterion>Subjects with Specific Stage/Type of COPD</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="3046">Subjects with acute exacerbation of COPD</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3076"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3112"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="3239"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Chronic obstructive pulmonary disease" id="24782">Subjects participating in any investigational drug/device study</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="20270"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Chronic obstructive pulmonary disease" id="27791"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2014-03-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-06-11T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-06-27T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="34738"><TitleDisplay>Risperidone (Risperdal) Augmentation in Depressed Partial Responders to Serotonin-norepinephrine reuptake inhibitor (SRI) Treatment</TitleDisplay><TitleOfficial>Risperidone (Risperdal) Augmentation in Depressed Partial Responders to SRI Treatment</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">030101</Identifier><Identifier type="NCT">NCT00178854</Identifier><Identifier type="Secondary Organisational">RIS-BIP-404</Identifier><Identifier type="Secondary Organisational">VUMC30141-R</Identifier><Identifier type="Secondary Organisational">RIS-USA-T31</Identifier></Identifiers><Indications><Indication id="93">Depression</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>risperidone</Name><Drug id="4236">risperidone</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4236">risperidone</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="17416">Janssen LP</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="20693">Vanderbilt University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="4236" type="Drug"><TargetEntity id="127142" type="siDrug">Risperidone</TargetEntity></SourceEntity><SourceEntity id="17416" type="Company"><TargetEntity id="5000410549" type="organizationId">Janssen LP</TargetEntity></SourceEntity><SourceEntity id="20693" type="Company"><TargetEntity id="4296216897" type="organizationId">Vanderbilt University</TargetEntity></SourceEntity><SourceEntity id="93" type="ciIndication"><TargetEntity id="10012378" type="MEDDRA"></TargetEntity><TargetEntity id="D003863" type="MeSH"></TargetEntity><TargetEntity id="-508468160" type="omicsDisease"></TargetEntity><TargetEntity id="53" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="13" type="Action"><TargetEntity id="948" type="Mechanism">5-HT2 Antagonists</TargetEntity></SourceEntity><SourceEntity id="150" type="Action"><TargetEntity id="125" type="Mechanism">Dopamine D2 Antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20693">Vanderbilt University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="17416">Janssen LP</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="13">5-HT 2 receptor antagonist</Action><Action id="150">Dopamine D2 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2943">Antipsychotic</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><DateStart>2004-05-31T00:00:00Z</DateStart><DateEnd type="actual">2006-12-01T00:00:00Z</DateEnd><DateChangeLast>2019-01-24T17:34:49Z</DateChangeLast><DateAdded>2008-11-12T03:45:11Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Vanderbilt University</Affiliation><Name>Ronald Salomon</Name></Contact><Contact type="Scientific contact"><Affiliation>Vanderbilt University Medical Center</Affiliation><Name>Ronald M Salomon, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Treatment-resistant unipolar depression (previous diagnosis of MDD by SCID-P or DSM-IV) as defined by inadequate or waning response to adequate SRI treatment for at least 4 weeks&lt;/li&gt;&lt;li&gt;HRSD (17-item) score &gt;/= 15 while taking an SRI with no past suicide attempts for one year and no current ideation, intent, or plan.   Repeat HRSD scores should remain &gt;/= 15 for 2 consecutive weeks after initial screening&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Adverse extrapyramidal or other response to dopamine antagonist effects in the past&lt;/li&gt;&lt;li&gt;Any adverse response to&lt;ulink linkType="Drug" linkID="4236"&gt;risperidone&lt;/ulink&gt; in the past&lt;/li&gt;&lt;li&gt;Residence beyond 30 miles from&lt;ulink linkType="Company" linkID="20693"&gt;Vanderbilt University&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Inability to comply with study requirements&lt;/li&gt;&lt;li&gt;Psychotic hallucinations&lt;/li&gt;&lt;li&gt;Past diagnosis of bipolar, dissociative, or psychotic disorders&lt;/li&gt;&lt;li&gt;Substance or alcohol abuse, other psychotropic, or any investigational or herbal preparation within 3 months or Substance dependency within 6 months prior to initial screening (by SCID-P)&lt;/li&gt;&lt;li&gt;History of impulsive suicidal gestures or attempts within two years (must have no suicidal ideation, intent or plan for a period of one year)&lt;/li&gt;&lt;li&gt;Primary diagnosis of Cluster B or C personality disorder, or significant comorbidity due to Borderline, Antisocial, Schizoid, or Schizotypal Personality Disorder (by SCID-II)&lt;/li&gt;&lt;li&gt;Seasonal affective syndromes, including seasonal affective disorder (because the duration of the study is long enough to expect spontaneous [natural] remissions)&lt;/li&gt;&lt;li&gt;Chronic (daily) benzodiazepine use in the past month or any use 1 week prior to sampling&lt;/li&gt;&lt;li&gt;Regular analgesic use.  No antipyretic medication is allowed in the pre- through post-sampling period, leaving difficulty with pain management for pain-prone patients&lt;/li&gt;&lt;li&gt;Medication use deemed by the investigator unacceptable for study protocol&lt;/li&gt;&lt;li&gt;Pregnancy or inability to cooperate with effective contraceptive method (double barrier)&lt;/li&gt;&lt;li&gt;Physical condition or significant medical history of any illness that presents risk with lumbar catheterization&lt;/li&gt;&lt;li&gt;Lactation&lt;/li&gt;&lt;li&gt;Blood donation within 90 days prior to or planned 90 days following the study&lt;/li&gt;&lt;li&gt;Severe migraine history&lt;/li&gt;&lt;li&gt;Daily tobacco use (absolute abstinence is required during the entire study)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary></MeasuresPrimary><MeasureSecondary><Measure><Description>Efficacy</Description></Measure><Measure><Description>Safety</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a study of the chemistry of depression in people who are taking an antidepressant but it is not working well.  The changes in brain chemicals that occur when an selective serotonin reuptake inhibitors (SSRIs) type antidepressant is supplemented with &lt;ulink linkType="Drug" linkID="4236"&gt;risperidone&lt;/ulink&gt; (Risperdal) would be studied.  Spinal fluid would be used to measure chemical levels of dopamine, serotonin, and other chemicals thought to be involved in depression.  The study would have the  potential to help understand and treat depression.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive risperidone  in depressed partial responders to serotonin-norepinephrine reuptake inhibitor (SRI) treatment.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;This study was been withdrawn prior to enrollment. Failed recruitment efforts.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Vanderbilt University Medical Center</Name><Address1>Nashville</Address1><Address2>Tennessee</Address2><Address3>37212</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Depression</Disease><PatientSegments><PatientSegment><PatientSegment id="7458">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00178854</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Depression" id="10787"><Endpoint>Assessment of Neuro-Transmitter Activity/Levels</Endpoint><SubEndpoints><SubEndpoint disease="Depression" id="10789">Assessment of serotonin</SubEndpoint><SubEndpoint disease="Depression" id="10790">Assessment of dopamine</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Depression" id="10791"><Endpoint>Assessment of Brain Structure and Function</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Depression" id="6400"><Criterion>Subjects with History/Diagnosis of Depression</Criterion></Inclusion><Inclusion disease="Depression" id="6402"><Criterion>Subjects with Major Depressive Disorder</Criterion></Inclusion><Inclusion disease="Depression" id="6420"><Criterion>Subjects Fulfilling Protocol Specific Diagnostic Criteria</Criterion><SubCriteria><SubCriterion disease="Depression" id="6421">Diagnosed by Diagnostic and Statistical Manual (DSM IV) criteria</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Depression" id="6432"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion><SubCriteria><SubCriterion disease="Depression" id="6436">Subjects with specified Hamilton depression rating score (HDRS)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Depression" id="6474"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Inclusion><Inclusion disease="Depression" id="6502"><Criterion>Subjects with Response to Therapy</Criterion></Inclusion><Inclusion disease="Depression" id="6507"><Criterion>Subjects with Treatment Resistant Disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Depression" id="8069"><Criterion>Subjects with Protocol Specified Clinical Manifestations</Criterion><SubCriteria><SubCriterion disease="Depression" id="8075">Subjects with suicidal ideation/suicide attempts</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="8086"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Depression" id="8091">Subjects with personality disorders</SubCriterion><SubCriterion disease="Depression" id="8092">Subjects with substance related disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="8093"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Depression" id="8088">Subjects co-morbid with bipolar disorder</SubCriterion><SubCriterion disease="Depression" id="8094">Subjects with central nervous system diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="8138"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Depression" id="8140">Subjects with history of other CNS therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Depression" id="8142"><Criterion>Subjects with Adverse Effects to Therapy</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2006-03-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2005-09-12T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-11-12T03:45:11Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="45450"><TitleDisplay>Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer</TitleDisplay><TitleOfficial>Phase I/II Trial of Preoperative Radiotherapy With Concurrent Bevacizumab, Erlotinib and Capecitabine for Locally Advanced Rectal Cancer</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>No</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">2007-0080</Identifier><Identifier type="NCT">NCT00543842</Identifier></Identifiers><Indications><Indication id="3671">Metastatic rectal cancer</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>bevacizumab</Name><Drug id="8047">bevacizumab</Drug></Intervention><Intervention type="InterventionPrimary"><Name>capecitabine</Name><Drug id="12205">capecitabine</Drug></Intervention><Intervention type="InterventionPrimary"><Name>erlotinib</Name><Drug id="11961">erlotinib</Drug></Intervention><Intervention type="InterventionPrimary"><Name>erlotinib + capecitabine + bevacizumab</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="11961">erlotinib</Drug><IndicationsPioneer><Indication id="3671">Metastatic rectal cancer</Indication></IndicationsPioneer><Companies><Company><Company id="19446">Roche Holding AG</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="19453">Genentech Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="23382">MD Anderson Cancer Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="12205">capecitabine</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="19446">Roche Holding AG</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="19453">Genentech Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="23382">MD Anderson Cancer Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="8047">bevacizumab</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="19446">Roche Holding AG</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="19453">Genentech Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="23382">MD Anderson Cancer Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="12205" type="Drug"><TargetEntity id="211639" type="siDrug">Capecitabine</TargetEntity></SourceEntity><SourceEntity id="8047" type="Drug"><TargetEntity id="223839" type="siDrug">Bevacizumab</TargetEntity></SourceEntity><SourceEntity id="11961" type="Drug"><TargetEntity id="250837" type="siDrug">Erlotinib hydrochloride</TargetEntity></SourceEntity><SourceEntity id="19446" type="Company"><TargetEntity id="4295890594" type="organizationId">Roche Holding AG</TargetEntity></SourceEntity><SourceEntity id="19453" type="Company"><TargetEntity id="4295912132" type="organizationId">Genentech Inc</TargetEntity></SourceEntity><SourceEntity id="23382" type="Company"><TargetEntity id="4296619331" type="organizationId">University of Texas MD Anderson Cancer Center</TargetEntity></SourceEntity><SourceEntity id="3671" type="ciIndication"><TargetEntity id="10055097" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="372" type="Action"><TargetEntity id="505" type="Mechanism">Thymidylate Synthase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3754" type="Action"><TargetEntity id="1222" type="Mechanism">HER (erbB) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="740" type="Action"><TargetEntity id="1071" type="Mechanism">EGFR (HER1; erbB1) Inhibitors</TargetEntity><TargetEntity id="1613" type="Mechanism">Anti-EGFR</TargetEntity><TargetEntity id="4344" type="Mechanism">EGFR (HER1; erbB1) (Mutant) Inhibitors</TargetEntity><TargetEntity id="4345" type="Mechanism">EGFR (Thr790Met Mutant) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="23382">MD Anderson Cancer Center</Company></CompaniesSponsor><CompaniesCollaborator><Company id="19446">Roche Holding AG</Company><Company id="19453">Genentech Inc</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="12521">VEGF ligand inhibitor</Action><Action id="372">Thymidylate synthase inhibitor</Action><Action id="3754">EGFR family tyrosine kinase receptor inhibitor</Action><Action id="740">Epidermal growth factor receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1569">Anticancer antimetabolite</Class><Class id="2953">Anti-inflammatory</Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="61">Angiogenesis inhibitor</Class><Class id="62255">Anticancer protein kinase inhibitor</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="751">Film coating</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="585">Oral formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="1652">Prodrug</Technology><Technology id="85">Protein recombinant</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>19</PatientCountEnrollment><PatientCountEvaluable>18</PatientCountEvaluable><DateStart>2007-12-31T00:00:00Z</DateStart><DateEnd type="actual">2013-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-12-14T07:11:13Z</DateChangeLast><DateAdded>2009-02-13T09:18:22Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>UT MD Anderson Cancer Center</Affiliation><Name>Prajnan Das, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>U.T.M.D. Anderson Cancer Center</Affiliation><Name>Prajnan Das</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&lt;/li&gt;&lt;li&gt;Patients must be&amp;gt;/= 18 years of age&lt;/li&gt;&lt;li&gt;All patients must have histologically confirmed adenocarcinoma of the rectum with pathological material reviewed by the Department of Pathology at MD Anderson cancer Center (MDACC)&lt;/li&gt;&lt;li&gt;Patients must have clinical stage II to III (T3, T4 or node-positive) based on computed tomography (CT), magnetic resonance (MR) or endoscopic ultrasound criteria&lt;/li&gt;&lt;li&gt;Patients must have no distant metastatic disease on chest, abdomen and pelvic CT scan performed with IV contrast. If the CT was performed outside of MDACC, the slice thickness must be&amp;lt;/= 7.5 mm. Criteria for pathological enlargement of lymph nodes is &amp;gt; 15 mm on short axis dimension&lt;/li&gt;&lt;li&gt;The rectal tumor must be either palpable on digital rectal exam or the inferior edge of the tumor must be within 12 cm of the anal verge based on rigid proctoscopy&lt;/li&gt;&lt;li&gt;Patients must have ANC&amp;gt;/= 1500/l, platelets &amp;gt;/= 100,000/mm3, total serum bilirubin &amp;lt;  2.0 mg%, BUN &amp;lt;/= 30 mg%, creatinine &amp;lt;/= 1.5 mg% and creatinine clearance &amp;gt;/= 30ml/min (estimated as calculated with Cockcroft-Gault equation). (Note: In patients with moderate renal impairment (estimated creatinine clearance 30 to 50 ml/min) at baseline, a dose reduction to 75% of the &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt; starting dose is recommended&lt;/li&gt;&lt;li&gt;Hemoglobin&amp;gt;/= 9 gm/dl (may be transfused to maintain or exceed this level)&lt;/li&gt;&lt;li&gt;Patients must have signed informed consent indicating that they are aware of the investigational nature of the study, and are aware that participation is voluntary. Patients must be made aware of their other treatment options&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Prior radiotherapy to the pelvis&lt;/li&gt;&lt;li&gt;Any prior chemotherapy&lt;/li&gt;&lt;li&gt;Prior VEGF or EGFR-directed therapy, such as&lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;, cetuximab, &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt;, or gefitinib&lt;/li&gt;&lt;li&gt;Current, prior or planned participation in any other experimental drug study&lt;/li&gt;&lt;li&gt;Pregnant or lactating woman. Woman of childbearing potential with either a positive or no pregnancy test at baseline. Women / men of childbearing potential not using a reliable contraceptive method (oral contraceptive, other hormonal contraceptive, intrauterine device, diaphragm or condom). (Postmenopausal woman must have been amenorrheic for at least 12 months to be considered of non-childbearing potential). Patients must agree to continue contraception for 30 days from the date of the last study drug administration&lt;/li&gt;&lt;li&gt;Serious, uncontrolled, concurrent infection(s) requiring iv antibiotics&lt;/li&gt;&lt;li&gt;Treatment for other clinically significant cancers within the last five years, except cured non-melanoma skin cancer and treated in-situ cervical cancer&lt;/li&gt;&lt;li&gt;Inadequately controlled hypertension [systolic blood pressure of&amp;gt; 130 and/or diastolic blood pressure of &amp;gt; 90 mmHg on antihypertensive medication at time of study entry and/or at time of starting therapy] history of myocardial infarction or unstable angina within 12 months prior to study enrollment, New York Heart Association Class II or greater congestive heart failure, unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia ie, atrial fibrillation or paroxysmal supraventricular tachycardia are eligible) or Class II or greater peripheral vascular disease&lt;/li&gt;&lt;li&gt;History of stroke or transient ischemic attack at any time,history of hypertensive crisis or hypertensive encephalopathy&lt;/li&gt;&lt;li&gt;Aspartate aminotransferase or alanine aminotransferase (AST or ALT)&amp;gt;/= 2.5 times the upper limit of normal&lt;/li&gt;&lt;li&gt;Inability to swallow oral medication&lt;/li&gt;&lt;li&gt;Evidence of bleeding diathesis or coagulopathy, INR&amp;gt;/= 2.5&lt;/li&gt;&lt;li&gt;Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0, or anticipation of need for major surgical procedure during the course of the study; fine needle aspirations or core biopsies within 7 days prior to day 0&lt;/li&gt;&lt;li&gt;Proteinuria at baseline or clinically significant impairment of renal function as demonstrated by either&lt;ul&gt;&lt;li&gt;Urine protein: creatinine ratio&amp;gt;/= 1.0 at screening&lt;/li&gt;&lt;li&gt;Urine dipstick for proteinuria&amp;gt;/= 2+ (patients discovered to have &amp;gt;/= 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 h urine collection and must demonstrate &amp;lt;/= 1g of protein in 24 h to be eligible)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Current serious, nonhealing wound, ulcer, or bone fracture&lt;/li&gt;&lt;li&gt;History of aortic aneurysm&amp;gt; 4.5 or aortic dissection&lt;/li&gt;&lt;li&gt;History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to day 0&lt;/li&gt;&lt;li&gt;Patients who have had an organ allograft&lt;/li&gt;&lt;li&gt;Patients on Coumadin are recommended to be changed to Low Molecular Weight Heparin (LMWH) at least 1 week prior to starting&lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt;. If patients cannot be switched to LMWH, then extra monitoring of their International Normalized Ratio (INR) will be performed&lt;/li&gt;&lt;li&gt;Patients taking Sorivudine or Brivudine must be off of these drugs for 4 weeks. Patients taking cimetidine must have this drug discontinued. Ranitidine or a drug from another anti-ulcer class can be substituted for cimetidine if necessary. If patient is currently receiving allopurinol, must discuss with PI to see of another agent may substitute for it&lt;/li&gt;&lt;li&gt;Patients with known Gilberts disease will be considered ineligible due to potential UGTA1 polymorphism effects on metabolism for&lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Inability to comply with study and/or follow-up procedures&lt;/li&gt;&lt;li&gt;Known hypersensitivity to any component of&lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Prior history of hypertensive crisis or hypertensive encephalopathy&lt;/li&gt;&lt;li&gt;Peripheral arterial thrombosis within 6 months prior to study enrollment&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Maximal tolerated dose (MTD)</Description><Timeframe>Continuoual reassessment weeks 1 to 6</Timeframe></Measure></MeasuresPrimary><MeasureSecondary></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;Results of this study published in 2012 showed that the probability of dose limiting toxicity at DL 4 was 0.15 [&lt;ulink linkType="Reference" linkID="1551436"&gt;1551436&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2013, results were published. None of the patient reported grade 4 acute toxicity, whereas one patient had grade 3 acute toxicity (hypertension). Grade 3 postoperative complications (ileus, small bowel obstruction, and infection) were observed in  three patients. With a median follow-up of 34 months, one patient had developed distant metastasis, and no patient had local recurrence or died. MTD was not reached [&lt;ulink linkType="Reference" linkID="1510949"&gt;1510949&lt;/ulink&gt;]. Similar results were published in 2012 [&lt;ulink linkType="Reference" linkID="1551436"&gt;1551436&lt;/ulink&gt;]. Similar results were published in February 2014  [&lt;ulink linkType="Reference" linkID="1551412"&gt;1551412&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The goal of this clinical research study is to find the highest tolerable dose of &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; (Avastin) and &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt; (Tarceva) that can be given in combination with standard radiation therapy and &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt; before surgery to patients with rectal cancer. The safety and effectiveness of this combination of therapies will also be studied.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results of this study published in 2012 showed that all 18 evaluable patients underwent surgery, with proctectomy with coloanal anastomosis in five (28%), and abdominoperineal resection in six (33%) patients. pCR was reported by eight patients (44%), and an additional eight patients (44%) had &amp;lt;/= 10% viable tumor in the surgical specimen. T downstaging was reported in fifteen patients (83%) [&lt;ulink linkType="Reference" linkID="1551436"&gt;1551436&lt;/ulink&gt;]. Similar results were published in February 2014  [&lt;ulink linkType="Reference" linkID="1551412"&gt;1551412&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2013, results were published. Of the 18 patients, pathological complete response was observed in eight patients and complete response of the primary tumor was observed in one patient with positive nodes. The disease-free survival was found to be 94% for three years [&lt;ulink linkType="Reference" linkID="1510949"&gt;1510949&lt;/ulink&gt;]. Similar results were published in February 2014  [&lt;ulink linkType="Reference" linkID="1551412"&gt;1551412&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results of this study published in February 2014 showed that all 18  patients underwent surgery, with low anterior resection in seven (39%), proctectomy with coloanal anastomosis in four  (22%), posterior pelvic exenteration in one (6%), and abdominoperineal resection in six (33%) patients  [&lt;ulink linkType="Reference" linkID="1551412"&gt;1551412&lt;/ulink&gt;]. &lt;br/&gt;&lt;br/&gt;&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Before the patients  can start treatment on this study, they  will have 'screening tests' to help the doctor decide if the patients  are eligible to take part in this study.  The following tests will be performed:
&lt;/para&gt;&lt;para&gt;Patients' will have a complete physical exam.
&lt;br/&gt;The study staff will review the medications the patients  are taking.  If necessary, the  prescriptions may be changed, in order to avoid any interactions with the study drugs.&lt;br/&gt;Blood will be drawn for routine tests.
&lt;br/&gt;A urine test will be performed.
&lt;br/&gt;They  will have computed tomography (CT) scans of the chest, abdomen and pelvis.
&lt;br/&gt;Women who are able to have children must have a negative urine pregnancy test.
&lt;/para&gt;&lt;para&gt;Study phases:
 the study has two parts, called phase I and phase II.  In the phase I portion, participants will be treated with one of four dose combinations of &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;, and &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt;, along with radiation therapy.  The dose level of &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt;  will change during phase I, but the dose levels of &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt; and radiation therapy is the same for all participants.  The first group of participants will be given the lowest dose combination.  If that group does not experience intolerable side effects, the next group of participants will be enrolled at a higher dose level.  This will continue until the highest tolerable dose level of the study drug and radiation therapy combination is found (called the maximum tolerated dose, or MTD).
 Based on the results of phase I, researchers will decide the MTD level of chemotherapy and radiation therapy.  In phase II, participants will be treated at the MTD dose level.  Up to 26 participants will be treated in each phase.
&lt;/para&gt;&lt;para&gt;Radiation and chemotherapy administration:
if the aptients  are found to be eligible to take part in this study, they  will begin radiation therapy.  The radiation therapy will be given once a day for 5 days in a row (Monday to Friday) each week, for up to 5 weeks and 3 days.  They  will have up to a total of 28 radiation treatments. Each radiation treatment will take about 30 min.
&lt;/para&gt;&lt;para&gt;Patients  will take the chemotherapy drug &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt; by mouth twice a day as a tablet on each of the days that patients receive radiation therapy. These pills will not be taken on Saturday and Sunday. They  must not be taking the drug cimetidine, and must be off of coumadin for at least 1 week and sorivudine and brivudine for at least 4 weeks before starting &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt; and during the entire &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt; therapy.  If they  are not able to stop taking coumadin, they  will need extra blood tests performed throughout the study to check  bleeding and clotting speed.
&lt;/para&gt;&lt;para&gt;Patients  will receive the drug &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; (5 mg/kg, iv, once q2w) for 6 weeks (a total of three doses).  The infusion will at first last 90 min. If there are no allergic reactions, fevers, or chills after the first infusion, the infusion time for the second dose will be shortened to 60 min.  If there is no allergic reactions or side effects during the second drug infusion, the last infusion of &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; will be given over 30 min.  If they  do have some reactions to the infusion, they  may receive extra preventive medications before the infusion, and the length of time may need to stay at 90 min.
&lt;/para&gt;&lt;para&gt;Patients will take the chemotherapy drug &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt;  (starting dose 50 mg, po, qd).  The  doctor will tell  whether the patients  will take &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt;  during the first 3 weeks of radiation therapy only, or during the whole time patients are getting radiation therapy, up to 6 weeks.
&lt;/para&gt;&lt;para&gt;Study tests:
during the study, patients' will have the following tests performed:
&lt;br/&gt;Physical exams once a week.
&lt;br/&gt;Every week, blood (about 2 teaspoons) will be drawn for routine tests.
&lt;br/&gt;Routine urine test in the first and third week of radiation therapy.
&lt;br/&gt;The possible development of side effects will be closely monitored during weekly visits with the doctors.
&lt;br/&gt;At 6 to 8 weeks after  patients  have stopped receiving radiotherapy, they  will have a physical exam, routine blood tests (about 2 teaspoons), and a urine test.
&lt;/para&gt;&lt;para&gt;Surgery:
at least 8 weeks after patients  have stopped receiving radiotherapy, they  will have the rectal tumor removed by surgery.  This is considered the standard of care and they  will sign a separate surgical consent document.
&lt;/para&gt;&lt;para&gt;Lenght of the study:
 patients will receive radiation therapy with &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt; (starting dose 650 mg/m2, po, bid), &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;, and &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt;  for five and a half  to 6 weeks.  At least 8 weeks after patients  stop receiving radiotherapy (30 min radiation treatments, dose of 50.4 Gy qd on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments), they  will have surgery.  Patients may then receive additional chemotherapy.
They  may be taken off study if the disease gets worse or patients experience intolerable side effects.
&lt;/para&gt;&lt;para&gt;Follow-up testing:
after surgery and possible chemotherapy after surgery, they  will be seen by a doctor every 3 to 4 months for one year, and then every 6 months for the next three years.  They  will have blood tests at these doctor visits.  They  will also have CT scans within 4 to 6 months after completion of chemotherapy then every 6 months for the first three years, and then once a year for the next two years.  These tests are all the standard of care procedures for treatment of colorectal cancer.
&lt;/para&gt;&lt;para&gt;This is an investigational study.  &lt;ulink linkType="Drug" linkID="12205"/&gt;Up to 52 patients will take part in the study.  All will be enrolled at &lt;ulink linkType="Company" linkID="23382"&gt;M. D. Anderson&lt;/ulink&gt;.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were treated in four escalating dose levels. Patients received preoperative radiation therapy with concurrent &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; (5 mg/kg iv, q2w), &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt;, and &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt; (dose was increased from 650  to 825 mg/m2, po, bid on the days of radiation therapy). The dose of &lt;ulink linkType="Drug" linkID="11961"&gt;erlotinib&lt;/ulink&gt; was increased from 50 mg po daily in weeks 1 to 3, to 50 mg daily in weeks 1 to 6, to 100 mg daily in weeks 1 to 6. At least 9 weeks after the last dose of &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;, patients underwent surgery [&lt;ulink linkType="Reference" linkID="1510949"&gt;1510949&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1551412"&gt;1551412&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>erlotinib + capecitabine + bevacizumab</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="1069">Metastasis</Indication><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="1519">Ileus</Indication><CountPatientsAffected>3</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="178">Hypertension</Indication><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="101070">bevacizumab</Intervention><Treatments><Treatment><Dose>5 milligram/kg</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="101071">capecitabine</Intervention><Treatments><Treatment><Dose>650 milligram/m2</Dose><Route>Oral</Route></Treatment><Treatment><Dose>825 milligram/m2</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="101072">erlotinib</Intervention><Treatments><Treatment><Dose>50 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>100 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>UT MD Anderson Cancer Center</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77030</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Colorectal tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3813">Subjects with Rectal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3822">Subjects with TNM stage II/Dukes B Colorectal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3823">Subjects with TNM stage III/Dukes C Colorectal Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00543842</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Colorectal tumor" id="8409"><Endpoint>Assessment of Mortality/Morbidity</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Colorectal tumor" id="8429"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8448">Assessment of postoperative complications</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Colorectal tumor" id="8451"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Colorectal tumor" id="9370"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="9369">Assessment of Complete Response</SubEndpoint><SubEndpoint disease="Colorectal tumor" id="9371">Assessment of clinical/pathological response</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Colorectal tumor" id="8151"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Colorectal tumor" id="8172"><Endpoint>Assessment of Disease Free Survival (DFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Colorectal tumor" id="8429"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8448">Assessment of postoperative complications</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Colorectal tumor" id="9370"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="9369">Assessment of Complete Response</SubEndpoint><SubEndpoint disease="Colorectal tumor" id="9375">Assessment of Clinical Benefit Rate (CBR)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Colorectal tumor" id="8440"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="8446">Assessment of surgery rates</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Colorectal tumor" id="8449"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="10381">Assessment of tumor down-staging</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Colorectal tumor" id="9370"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Colorectal tumor" id="9371">Assessment of clinical/pathological response</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Colorectal tumor" id="4467"><Criterion>Subjects with Rectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4470"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4472">Subjects with protocol specified lesion dimensions/location</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="4481"><Criterion>Subjects with TNM Stage II/Dukes B Colorectal Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4483"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Colorectal tumor" id="4526"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4527">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Colorectal tumor" id="4528">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="32554"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4564">Subjects with normal/acceptable liver function</SubCriterion><SubCriterion disease="Colorectal tumor" id="4569">Subjects with normal/acceptable hematopoetic/marrow function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Colorectal tumor" id="33970"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="4565">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Colorectal tumor" id="5825"><Criterion>Subjects with Metastatic Colorectal Cancer</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5848"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5856"><Criterion>Subjects co-morbid with inflammatory disorders</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5860"><Criterion>Subjects co-morbid with CNS disorders</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5864"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5879"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5885">Subjects co-morbid with hematological disease/disorders</SubCriterion><SubCriterion disease="Colorectal tumor" id="5886">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="5887"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5918"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5920">Subjects with hypersensitivity/contraindication to biological therapy</SubCriterion><SubCriterion disease="Colorectal tumor" id="5921">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="5928"><Criterion>Subjects with History of/Scheduled to Receive Colorectal Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5938">Subjects with history of/scheduled to receive targeted therapy</SubCriterion><SubCriterion disease="Colorectal tumor" id="20284">Subjects with history of/scheduled to receive intervention/surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="5945"><Criterion>Subjects with history of/scheduled to receive biological therapy</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5949"><Criterion>Subjects with history of/scheduled to receive radiation therapy</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="5954"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5955">Subjects with history of/scheduled for biopsy</SubCriterion><SubCriterion disease="Colorectal tumor" id="5959">Subjects with history of/scheduled for transplantation</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Colorectal tumor" id="5962"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Colorectal tumor" id="26894"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Colorectal tumor" id="5934">Subjects with history of/scheduled for chemotherapy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2013-12-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2011-01-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>37.03 Months</EnrollmentPeriod><EnrollmentRate>0.51 Patients/Month</EnrollmentRate><DateFirstReceived>2007-10-11T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-02-13T09:18:22Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2013-12-12T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2013-12-23T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="47636"><TitleDisplay>Effect of Sitagliptin on Graft Function Following Islet Transplantation</TitleDisplay><TitleOfficial>A Randomized Controlled Trial to Determine if Sitagliptin Will Enhance Islet Graft Function When Given for One Year Following Transplantation</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">H08-01947</Identifier><Identifier type="NCT">NCT00853944</Identifier></Identifiers><Indications><Indication id="2986">Pancreas transplantation</Indication></Indications><BiomarkerNames></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>sitagliptin</Name><Drug id="44499">sitagliptin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44499">sitagliptin</Drug><IndicationsPioneer><Indication id="2986">Pancreas transplantation</Indication></IndicationsPioneer><Companies><Company><Company id="1059823">Merck Sharp &amp; Dohme Corp</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="20532">University of British Columbia</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="44499" type="Drug"><TargetEntity id="333966" type="siDrug">Sitagliptin phosphate monohydrate</TargetEntity></SourceEntity><SourceEntity id="1059823" type="Company"><TargetEntity id="4295904507" type="organizationId">Merck Sharp &amp; Dohme Corp</TargetEntity></SourceEntity><SourceEntity id="20532" type="Company"><TargetEntity id="4296804583" type="organizationId">University of British Columbia</TargetEntity></SourceEntity><SourceEntity id="2986" type="ciIndication"><TargetEntity id="10058845" type="MEDDRA"></TargetEntity><TargetEntity id="D016035" type="MeSH"></TargetEntity><TargetEntity id="-485238992" type="omicsDisease"></TargetEntity><TargetEntity id="1089" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="5537" type="Action"><TargetEntity id="415" type="Mechanism">Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors</TargetEntity><TargetEntity id="3328" type="Mechanism">Anti-CD26 (Anti-Dipeptidyl Peptidase IV; DPPIV)</TargetEntity><TargetEntity id="5399" type="Mechanism">Dipeptidyl peptidase 4 (DPP4) antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20532">University of British Columbia</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1059823">Merck Sharp &amp; Dohme Corp</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="5537">Dipeptidyl peptidase IV inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="3313">Glucagon-like peptide 1 metabolism modulator</Class><Class id="38439">DPP IV inhibitor antidiabetic product</Class><Class id="399">Hypoglycemic agent</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>12</PatientCountEnrollment><DateStart>2009-07-31T00:00:00Z</DateStart><DateEnd type="actual">2013-11-01T00:00:00Z</DateEnd><DateChangeLast>2019-01-24T17:36:04Z</DateChangeLast><DateAdded>2009-03-03T11:11:03Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>University of British Columbia</Affiliation><Name>David M. Thompson</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Type 1 diabetes for  greater than five  years with negative C peptide, GFR&amp;gt; 70 ml/min, BMI &amp;lt;/= 28 and
             non-smoker for &gt;/= 1 year&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Known hypersensitivity to&lt;ulink linkType="Drug" linkID="44499"&gt;sitagliptin&lt;/ulink&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Islet function as measured by hyperglycemic clamp</Description><Timeframe>3 and 12  months +/- 2 weeks after islet infusion</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change in insulin requirement (absolute and % decrease from pre-transplant dose)</Description><Timeframe>1 week prior to stopping the study</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study was designed to test this
      hypothesis using &lt;ulink linkType="Drug" linkID="44499"&gt;sitagliptin&lt;/ulink&gt; in a randomized clinical trial.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study was designed to determine if &lt;ulink linkType="Drug" linkID="44499"&gt;sitagliptin&lt;/ulink&gt; given at the time of an islet cell transplant (ICT)
      results in improved islet graft function at 3 and 12 months post-transplant.
&lt;br/&gt;This was a  prospective, randomized, double-blind, single-centre, placebo-controlled
      trial.      Sample size calculation for primary outcome.
&lt;/para&gt;&lt;para&gt;The primary outcome (stimulated insulin secretion) was a continuous variable that is normally
      distributed.  &lt;/para&gt;&lt;para&gt;Eligible patients would be those in the transplant program who are about to
      undergo an infusion of donor islets. Criteria for entry into the program are as described
      (Warnock et al Arch Surg 2005;140:735).  All eligible patients would be offered a chance to
      enter the study.  Patients would need to sign an informed consent that has been approved by
      the Clinical Research Ethics Board of the &lt;ulink linkType="Company" linkID="20532"&gt;University of British Columbia&lt;/ulink&gt;.
&lt;/para&gt;&lt;para&gt;The subject and the investigators obtaining consent, performing the transplant, providing
      post-transplant care and performing the hyperglycemic clamp would be blind as to whether a
      subject was receiving &lt;ulink linkType="Drug" linkID="44499"&gt;sitagliptin&lt;/ulink&gt; or placebo. The placebo would be supplied by &lt;ulink linkType="Company" linkID="18077"&gt;Merck&lt;/ulink&gt; and will
      be identical in appearance to &lt;ulink linkType="Drug" linkID="44499"&gt;sitagliptin&lt;/ulink&gt;.  &lt;ulink linkType="Drug" linkID="44499"&gt;Sitagliptin&lt;/ulink&gt; and the placebo would be stored in the
      VGH pharmacy.
&lt;/para&gt;&lt;para&gt;When a subject consents to participate in the study, the investigator obtaining the consent
      would contact the pharmacy. The pharmacy would open the next randomization envelope and
      dispense the medication (&lt;ulink linkType="Drug" linkID="44499"&gt;sitagliptin&lt;/ulink&gt; or placebo). Ongoing supply of the medication would be
      provided by the pharmacy in the transplant clinic during routine follow-up visits for
      post-transplant care.
&lt;/para&gt;&lt;para&gt;Patient care:
     all aspects of the transplantation procedure, immunosuppressive therapy and ancillary care
      would be performed as described (Warnock et al Arch Surg 2005;140:735) and would be similar for
      all patients for the duration of the study.  The indications for stopping or restarting
      insulin are those recommended by the metabolic monitoring committee of the Collaborative
      Islet Transplant Registry.  This would eliminate subjective investigator judgments that could
      affect one of the secondary endpoints (insulin dose).
&lt;/para&gt;&lt;para&gt;Assessment of endpoints:&lt;br/&gt;Primary: Maximum insulin secretory capacity would be determined by a hyperglycemic glucose
      clamp, performed as described (Al Ghofaili et al Transplantation 2007;83:24).  This would be
      performed at 3 and 12  months +/- 2 weeks after islet infusion, with the subject having
      received either &lt;ulink linkType="Drug" linkID="44499"&gt;sitagliptin&lt;/ulink&gt; or placebo during this period. The medication would be stopped for
      48 h before the clamp to allow washout.  A positive result would suggest that &lt;ulink linkType="Drug" linkID="44499"&gt;sitagliptin&lt;/ulink&gt;
      had increased functional islet mass, not that it was acting as a short-term secretagogue.
      The values would be expressed both as absolute numbers and as divided by the number of IE / kg
      received as it was not clear from the literature which is the better measurement. A baseline
      fasting C peptide would be drawn prior to the islet infusion.
&lt;/para&gt;&lt;para&gt;Secondary: patients would be followed closely post transplant to maintain tight glucose control.
      Insulin adjustment and glucose targets are as described.  The average daily insulin
      requirement in the week before transplant and in the week prior to stopping the study would be
      used for calculation. A positive result would be consistent with either an increase in
      functional islet mass or stimulation or insulin secretion.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;The study was terminated as sponsor withdrew funding du to lack of enrollment. Lack of enrollment was due to decrease in number of islet transplant procedures.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>Vancouver General Hospital</Name><Address1>Vancouver</Address1><Address2>British Columbia</Address2><CountrySubDivision>British Columbia</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="7594">Subjects with Negative C-peptide Levels</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7640">Subjects Requiring/Scheduled for Other Anti-diabetic Therapy</PatientSegment><SubSegments><SubSegment id="7642">Subjects requiring/scheduled for islet cell transplant</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00853944</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Insulin dependent diabetes" id="18156"><Endpoint>Assessment of Beta Cell Function</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Insulin dependent diabetes" id="18206"><Endpoint>Assessment of Insulin Dose</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Insulin dependent diabetes" id="16300"><Criterion>Subjects with Detectable /Low C-peptide Levels</Criterion></Inclusion><Inclusion disease="Insulin dependent diabetes" id="35101"><Criterion>Subjects with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="16827">Subjects with Type 1 Diabetes Mellitus</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Insulin dependent diabetes" id="13861"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2013-11-01T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2009-02-26T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-03-03T11:11:03Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2017-11-22T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="62929"><TitleDisplay>Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy</TitleDisplay><TitleOfficial>Catheter-based Transendocardial Delivery of Autologous Bone Marrow-Derived Cells in Patients With Heart Failure Due to Dilated Cardiomyopathy</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Yes</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">ABI-55-0811-1</Identifier><Identifier type="NCT">NCT01020968</Identifier></Identifiers><Indications><Indication id="3422">Dilated cardiomyopathy</Indication><Indication id="55">Cardiac failure</Indication></Indications><BiomarkerNames><BiomarkerName id="96" role="Therapeutic effect marker" type="Genomic;Proteomic">Troponin I, cardiac muscle</BiomarkerName><BiomarkerName id="105" role="Therapeutic effect marker" type="Genomic;Proteomic">Natriuretic peptides B</BiomarkerName><BiomarkerName id="147" role="Therapeutic effect marker" type="Physiological">Six-minute walk distance</BiomarkerName><BiomarkerName id="1945" role="Therapeutic effect marker" type="Physiological">Left ventricular ejection fraction</BiomarkerName><BiomarkerName id="9580" role="Therapeutic effect marker" type="Structural (imaging)">Left ventricle</BiomarkerName><BiomarkerName id="9750" role="Therapeutic effect marker" type="Structural (imaging)">Right ventricle</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ixmyelocel-T</Name><Drug id="55530">ixmyelocel-T</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>standard of Care</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="55530">ixmyelocel-T</Drug><IndicationsPioneer><Indication id="55">Cardiac failure</Indication></IndicationsPioneer><Companies><Company><Company id="13596">Vericel Corp</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="55530" type="Drug"><TargetEntity id="461793" type="siDrug">Ixmyelocel-T</TargetEntity></SourceEntity><SourceEntity id="13596" type="Company"><TargetEntity id="4295905396" type="organizationId">Vericel Corp</TargetEntity></SourceEntity><SourceEntity id="3422" type="ciIndication"><TargetEntity id="I42.0" type="ICD10"></TargetEntity><TargetEntity id="D002311" type="MeSH"></TargetEntity><TargetEntity id="213" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="55" type="ciIndication"><TargetEntity id="I50" type="ICD10"></TargetEntity><TargetEntity id="10007554" type="MEDDRA"></TargetEntity><TargetEntity id="D006333" type="MeSH"></TargetEntity><TargetEntity id="-1323949873" type="omicsDisease"></TargetEntity><TargetEntity id="237" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>3</NumberOfSites><CompaniesSponsor><Company id="13596">Vericel Corp</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><Class><Class id="2659">Cardioprotectant</Class><Class id="2660">Vasoprotectant</Class><Class id="62">Angiogenesis stimulator</Class></Class><Technologies><Technology id="856">Autologous stem cell therapy</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="884">Haematopoietic stem cell therapy</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="864">Mesenchymal stem cell therapy</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>22</PatientCountEnrollment><DateStart>2009-12-31T00:00:00Z</DateStart><DateEnd type="actual">2013-12-31T00:00:00Z</DateEnd><DateChangeLast>2019-05-10T02:06:11Z</DateChangeLast><DateAdded>2009-12-31T07:05:38Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>University Hospitals</Affiliation><Name>Marco Costa</Name></Contact><Contact type="Public contact"><Email>mail@aastrom.com</Email><Name>Judy Douville</Name><Phone>734-930-5555</Phone></Contact><Contact type="Public contact"><Affiliation>University of Utah</Affiliation><Email>Kristin.Kolsch@hsc.utah.edu</Email><Name>Kristin Kolsch</Name><Phone>801-585-6743</Phone></Contact><Contact type="Public contact"><Affiliation>University of Utah</Affiliation><Email>Patty.meldrum@hsc.utah.edu</Email><Name>Patty Meldrum</Name><Phone>801-581-4121</Phone></Contact><Contact type="Public contact"><Affiliation>Minneapolis Heart Institute</Affiliation><Email>Patricia.Mitchell@allina.com</Email><Name>Patricia Mitchell</Name><Phone>612-863-6287</Phone></Contact><Contact type="Public contact"><Affiliation>University Hospitals</Affiliation><Email>Terence.Semenec@UHhospitals.org</Email><Name>Terence Semenec</Name><Phone>216-983-4724</Phone></Contact><Contact type="Scientific contact"><Affiliation>Minneapolis Heart Institute Foundation</Affiliation><Name>Timothy Henry</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Diagnosis of ischemic or non-ischemic dilated cardiomyopathy according to WHO
             criteria. Ischemic: DCM in a patient with a history of myocardial infarction or
             evidence of clinically significant (&amp;gt;/= 70% narrowing of a major epicardial artery)
             coronary artery disease. Non-ischemic: dilation and impaired contraction of left
             ventricle or both ventricles of idiopathic, familial/genetic, viral and/or immune,
             toxic origin, or associated with recognized cardiovascular disease in which the
             degree of myocardial dysfunction is not explained by normal loading conditions or the
             extent of ischemic damage&lt;/li&gt;&lt;li&gt;No other cardiac surgery or percutaneous cardiac interventions likely to produce
             clinical improvement, as determined by an interventional cardiologist (for PTCA) and
             a cardiothoracic surgeon (for CABG).  This condition is satisfied in patients
             with chronic ischemic disease who have previously been successfully revascularized but
             have failed to show clinical improvement. All patients who are candidates for
             revascularization are ineligible for participation&lt;/li&gt;&lt;li&gt;LVEF&amp;lt;/= 30% by echocardiogram within 30 days prior to randomization&lt;/li&gt;&lt;li&gt;Symptomatic heart failure in NYHA class III or IV&lt;/li&gt;&lt;li&gt;Able to comply with scheduled visits in cardiac out-patient clinic&lt;/li&gt;&lt;li&gt;Able to tolerate study procedures, including bone marrow aspiration, cardiac CT,
             metabolic stress test, 6 min walk test&lt;/li&gt;&lt;li&gt;Males and females, 18 to 86 years of age&lt;/li&gt;&lt;li&gt;Life expectancy of 6 months or more in the opinion of the investigator&lt;/li&gt;&lt;li&gt;Able to give informed consent&lt;/li&gt;&lt;li&gt;Normal organ and marrow function (leukocytes&amp;gt;/= 3000/microg, absolute neutrophil
             count &amp;gt;/= 1500/microg, platelets &amp;gt;/= 140,000/microg, AST(SGOT)/ALT (SGPT) &amp;lt;/=
             2.5 x institutional standards range and creatinine &amp;lt;/= 2.5 mg/dl)&lt;/li&gt;&lt;li&gt;Controlled blood pressure (systolic blood pressure&amp;lt;/= 140; diastolic blood pressure
             &amp;lt;/= 90 mmHg) and established anti-hypertensive therapy as necessary prior to entry
             into the study&lt;/li&gt;&lt;li&gt;Stable, standard medical therapy for DCM for at least 1 month with no new medications
             to treat the disease introduced in the last 3 months. Standard medical therapy
             includes: placement of AICD unless contraindicated (refusal of AICD not considered
             valid contraindication), use of ACE inhibitors and/or AT-1 receptor blockers as well
             as loop diuretics unless contraindicated and, depending on the type of heart failure
             associated with the disease, standard therapy may also include use of vasodilators,
             beta blockers, digoxin, and aldosterone or other medications&lt;/li&gt;&lt;li&gt;Pre-existing conditions are adequately controlled in the opinion of the investigator&lt;/li&gt;&lt;li&gt;Fertile patients must agree to use an appropriate form of contraception while
             participating in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Severe primary valvular heart disease including, but not limited to, aortic valve
             stenosis and insufficiency&lt;/li&gt;&lt;li&gt;Known history of COPD defined as Gold stage IIB (FEV1/FVC&amp;lt; 70% with 30% &amp;lt;/= FEV1 &amp;lt; 50 %
             predicted, with or without chronic symptoms of cough, sputum production, dyspnea) or
             more severe or restrictive pulmonary disease&lt;/li&gt;&lt;li&gt;Known history of primary pulmonary hypertension&lt;/li&gt;&lt;li&gt;VAD implantation&lt;/li&gt;&lt;li&gt;Myocardial infarction within 4 weeks prior to randomization&lt;/li&gt;&lt;li&gt;History of life-threatening ventricular arrhythmia, except if an AICD is implanted&lt;/li&gt;&lt;li&gt;Unstable angina, characterized by increasingly frequent episodes with modest exertion
             or at rest, worsening severity, and prolonged duration&lt;/li&gt;&lt;li&gt;Patients at high risk for complications due to injection procedure (eg, patients who
             have severe peripheral atherosclerotic disease that does not allow advancement of the
             catheter; patients who have a prosthetic aortic or mitral valve; patients who have a
             LV thrombus or aneurysm; patients who have an aortic dissection or aneurysm, etc)&lt;/li&gt;&lt;li&gt;Patients with poorly controlled diabetes mellitus (HbAlc&amp;gt; 9.0%)&lt;/li&gt;&lt;li&gt;Patients receiving treatment with hematopoietic growth factors (eg, EPO, G-CSF)&lt;/li&gt;&lt;li&gt;Patients who require uninterruptible anticoagulation therapy (eg, warfarin) that
             cannot be stopped for 72 h prior to bone marrow aspiration and intramyocardial
             injections; or patients receiving anti-platelet therapy (eg, clopidogrel) that
             cannot be stopped for 7 days prior to bone marrow aspiration and transendocardial
             injections, unless contraindicated&lt;/li&gt;&lt;li&gt;Known cancer and undergoing treatment including chemotherapy and radiation&lt;/li&gt;&lt;li&gt;Patients requiring continuous, systemic, high dose corticosteroid therapy (more than
             7.5 mg/day) within 1 month before aspiration or 6 months after injection procedure&lt;/li&gt;&lt;li&gt;End stage renal disease requiring dialysis&lt;/li&gt;&lt;li&gt;Patients pregnant or lactating; positive for hCG&lt;/li&gt;&lt;li&gt;History of alcohol consumption regularly exceeding the equivalent of 2 drinks/day (1
             drink = 5 oz of wine or 12 oz [360 ml] of beer or 1.5 oz [45 ml]) of hard liquor or
             history of illicit drug use within 6 months of screening&lt;/li&gt;&lt;li&gt;Known allergies to protein products (horse or bovine serum, or porcine trypsin) used
             in the ex-vivo cell production process&lt;/li&gt;&lt;li&gt;BMI of 40 kg/m2 or greater&lt;/li&gt;&lt;li&gt;Patients receiving experimental medications or participating in another clinical
             study within 30 days of screening&lt;/li&gt;&lt;li&gt;HIV or syphilis, positive at time of screening&lt;/li&gt;&lt;li&gt;Active hepatitis B or hepatitis C infection at the time of screening&lt;/li&gt;&lt;li&gt;Patient determined unsuitable for cellular therapy, in the opinion of the
             investigator or sponsor&lt;/li&gt;&lt;li&gt;Patients receiving anti-angiogenic drugs (eg, anti-VEGF)&lt;/li&gt;&lt;li&gt;Known allergy or sensitivity to contrast agents used in imaging procedures&lt;/li&gt;&lt;li&gt;Minimum LV wall thickness of&amp;lt; 6 mm as determined by ECHO&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Incidence of major adverse cardiac event (MACE) (MACE defined as: cardiac death, cardiac arrest, myocardial infarction, sustained ventricular arrhythmias, pulmonary edema, acute heart failure, unstable angina and major bleeding)</Description><Timeframe>At baseline, month 3, 6 and 12</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Left ventricular ejection fraction (LVEF) (as determined by Echo, Cardiac CT and SPECT)</Description><Timeframe>At baseline, month 3, 6 and 12. CT and SPECT are only assessed at baseline and month 6</Timeframe></Measure><Measure><Description>Change in LV and RV dimensions and in LV volumes (as determined by Echo, Cardiac CT and SPECT)</Description><Timeframe>At baseline, month 3, 6 and 12. CT and SPECT are only assessed at baseline and month 6</Timeframe></Measure><Measure><Description>Wall Motion Score Index (WMSI) (as determined by Echo, Cardiac CT and SPECT)</Description><Timeframe>At baseline, month 3, 6 and 12. CT and SPECT are only assessed at baseline and month 6</Timeframe></Measure><Measure><Description>Assessment of myocardial perfusion in ischemic patient cohort, only (as determined by SPECT)</Description><Timeframe>Baseline and month 3</Timeframe></Measure><Measure><Description>Exercise tolerance (6 min walk test)</Description><Timeframe>At baseline, month 3, 6 and 12</Timeframe></Measure><Measure><Description>Heart failure status (as determined by New York Heart Association (NYHA) heart failure status (NYHA) class and Brain Natriuretic Peptide [BNP])</Description><Timeframe>At baseline, month 3, 6 and 12</Timeframe></Measure><Measure><Description>Angina status (as determined by Canadian Cardiovascular Society (CCS) classification and Troponin I Levels)</Description><Timeframe>At baseline, month 3, 6 and 12</Timeframe></Measure><Measure><Description>Quality of life (as determined by Minnesota Living with Heart Failure Questionnaire [MLHFQ])</Description><Timeframe>At baseline, month 3, 6 and 12</Timeframe></Measure><Measure><Description>Pulmonary function (as determined by metabolic stress test)</Description><Timeframe>Baseline, month 6 and 12</Timeframe></Measure><Measure><Description>Device implantation, transplantation and positive inotrope use (as determined by incidence rates)</Description><Timeframe>At baseline, month 3, 6 and 12</Timeframe></Measure><Measure><Description>AICD firing rate</Description><Timeframe>At baseline, month 3, 6 and 12</Timeframe></Measure><Measure><Description>Changes in medication for heart failure</Description><Timeframe>At baseline, month 3, 6 and 12</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study was designed to assess the safety profile and the efficacy of &lt;ulink linkType="Drug" linkID="55530"&gt;ixmyelocel-T&lt;/ulink&gt; administered via catheter in treating patients with dilated cardiomyopathy (DCM).&lt;/para&gt;&lt;para&gt;By May 2010, the first patient was treated [&lt;ulink linkType="Reference" linkID="1100141"&gt;1100141&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;The pooled results from two separate trials (&lt;ulink linkType="Protocol" linkID="30076"&gt;NCT00765518&lt;/ulink&gt;  and &lt;ulink linkType="Protocol" linkID="62929"&gt;NCT01020968&lt;/ulink&gt;) were published in August 2014. Of the 61 patients randomized, 59 received the drug or the standard care. When compared with the control group, the treatment group (patients who recieved ixmyelocel-T  experienced decreased occurance of major adverse cardiovascular events and improved measures of symptoms as assessed by New York Heart Association classification system, a 6 min walk test, and the Minnesota Living with Heart Failure Questionnaire [&lt;ulink linkType="Reference" linkID="1587681"&gt;1587681&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study would be a prospective, stratified, randomized, open-label, controlled, multicenter
      study to assess the safety profile and the efficacy of ixmyelocel-T administered via catheter in
      treating patients with DCM.  A total of two strata would be used: ischemic (IDCM) and non-ischemic
      (NIDCM).  Within each stratum, patients would be   randomized to receive either ixmyelocel-T treatment
      or control in a 2 : 1 ratio (eight patients per ixmyelocel-T treatment group and four patients per control
      group).  It would enroll a total of 24 patients at two sites in the US.&lt;/para&gt;&lt;para&gt;Arm 1 (ixmyelocel-T): the treatment arm of the study would receive catheter-based injections of the study cellular product (CRCs would be administered via catheter-based injection to the endocardial surface of the left ventricle).&lt;br/&gt;Arm 2: would receive approximately 12 to 20 intramyocardial injections of 0.4 ml each of vehicle control into the left ventricle.&lt;br/&gt;&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Minneapolis Heart Institute</Name><Address1>Minneapolis</Address1><Address2>Minnesota</Address2><Address3>55407</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University Hospitals, Case Western Reserve University</Name><Address1>Cleveland</Address1><Address2>Ohio</Address2><Address3>44106</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts></Contacts></Site><Site><Name>University of Utah</Name><Address1>Salt Lake City</Address1><Address2>Utah</Address2><Address3>84112</Address3><CountrySubDivision code="UT">Utah</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Myocardial disease</Disease><PatientSegments><PatientSegment><PatientSegment id="11228">Subjects with Heart Failure Secondary to Cardiomyopathy</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Cardiac failure</Disease><PatientSegments><PatientSegment><PatientSegment id="61">Subjects with Symptomatic Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="82">Subjects with comorbid conditions</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="13416">Subjects with NYHA Functional Class	</PatientSegment><SubSegments><SubSegment id="77">Moderate/NYHA Functional Class III Heart Failure Subjects</SubSegment><SubSegment id="78">Severe/NYHA Functional Class IV Heart Failure Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Stem cell transplantation</Disease><PatientSegments><PatientSegment><PatientSegment id="10721">Subjects with H/O of Cardiovascular Diseases/ Disorders Indicated for SCT</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Coronary artery disease</Disease><PatientSegments><PatientSegment><PatientSegment id="198">Subjects with Complications of the Underlying IHD</PatientSegment><SubSegments><SubSegment id="200">Subjects with congestive heart failure</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="243">Subjects with Abnormal Angiographic Findings</PatientSegment><SubSegments><SubSegment id="250">Stenosis or lesion of one major epicardial artery</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="368">Subjects with Myocardial Ischemia</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01020968</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Cardiac failure" id="609"><Endpoint>Hematological Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Cardiac failure" id="973"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="983">Other cardiovascular mortality</SubEndpoint><SubEndpoint disease="Cardiac failure" id="984">Heart failure mortality</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Cardiac failure" id="1321"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="563">Edema</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Coronary artery disease" id="2491"><Endpoint>Assessment of Cardiovascular Events</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2492">Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)</SubEndpoint><SubEndpoint disease="Coronary artery disease" id="2503">Unstable angina</SubEndpoint><SubEndpoint disease="Coronary artery disease" id="2619">Assessment of major adverse cardiac events (MACEs)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Coronary artery disease" id="2609"><Endpoint>Assessment of Other Cardiovascular Events</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2616">Heart failure (New onset /Worsening)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Coronary artery disease" id="2621"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2622">Cardiovascular mortality</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Coronary artery disease" id="2652"><Endpoint>Assessment of Hemorrhagic Complications</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2654">Major/minor bleeding</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Cardiac failure" id="6790"><Endpoint>Assessment of Cardiovascular Events</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="561">Assessment of major adverse cardiac events (MACEs)</SubEndpoint><SubEndpoint disease="Cardiac failure" id="688">Angina pectoris</SubEndpoint><SubEndpoint disease="Cardiac failure" id="690">Assessment of fatal/non-fatal myocardial infarction</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Stem cell transplantation" id="17460"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Stem cell transplantation" id="17461">Assessment of adverse events/serious adverse events</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Myocardial disease" id="24729"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Myocardial disease" id="24731">Cardiovascular mortality</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Myocardial disease" id="24774"><Endpoint>Assessment of Cardiovascular Events</Endpoint><SubEndpoints><SubEndpoint disease="Myocardial disease" id="24772">Assessment of major adverse cardiac events (MACEs)</SubEndpoint><SubEndpoint disease="Myocardial disease" id="24780">Assessment of myocardial infarction</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Myocardial disease" id="24789"><Endpoint>Assessment of Non Cardiovascular  Events</Endpoint><SubEndpoints><SubEndpoint disease="Myocardial disease" id="24794">Assessment of pulmonary functions or events</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Coronary artery disease" id="44782"><Endpoint>Assessment of Clinical Symptoms</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2610">Assessment of arrhythmia</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Myocardial disease" id="44785"><Endpoint>Assessment of Clinical Symptoms</Endpoint><SubEndpoints><SubEndpoint disease="Myocardial disease" id="24775">Assessment of arrhythmia</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Cardiac failure" id="44786"><Endpoint>Assessment of Clinical Symptoms</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="587">Assessment of arrhythmia</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Cardiac failure" id="641"><Endpoint>Assessment of Cardiac Markers</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="654">Plasma B-type natriuretic peptide (BNP)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="662"><Endpoint>Assessment of Cardiac Function</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="917">Assessment of left ventricular ejection fraction (LVEF)</SubEndpoint><SubEndpoint disease="Cardiac failure" id="1003">Myocardial perfusion measures</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="732"><Endpoint>Assessment of Exercise Capacity/Tolerance</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="737">Change in NYHA functional status</SubEndpoint><SubEndpoint disease="Cardiac failure" id="753">Six-minute walk test (6MWT)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="909"><Endpoint>Assessment of Ventricular Structure/Dimension/Function</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="915">Left ventricular diastolic volume</SubEndpoint><SubEndpoint disease="Cardiac failure" id="939">Left ventricular size</SubEndpoint><SubEndpoint disease="Cardiac failure" id="943">Left ventricular systolic volume</SubEndpoint><SubEndpoint disease="Cardiac failure" id="945">Left ventricular wall motion score index (WMSI)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="1203"><Endpoint>Assessment of Pulmonary Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="1305"><Endpoint>Assessment of Right Ventricular Structure and Function</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="1317">Right ventricular size</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="2178"><Endpoint>Assessment of Device Related Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="2187">Frequency of Use of Device</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Coronary artery disease" id="2491"><Endpoint>Assessment of Cardiovascular Events</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2493">Angina frequency/severity/Duration/Rate of ischemic episodes</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Coronary artery disease" id="2519"><Endpoint>Assessment of Cardiac Markers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Coronary artery disease" id="2666"><Endpoint>Assessment of Procedure and Procedure Related Events</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2681">Implantable Cardioverter Defibrillator (ICD) therapy</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Coronary artery disease" id="2728"><Endpoint>Assessment of Cardiac Function</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2730">Baseline and post-treatment measurements of left ventricle (LV) size</SubEndpoint><SubEndpoint disease="Coronary artery disease" id="2733">Assessment of ejection fraction</SubEndpoint><SubEndpoint disease="Coronary artery disease" id="2734">Functional capacity - subjective by NYHA class</SubEndpoint><SubEndpoint disease="Coronary artery disease" id="2738">Assessment by wall motion score index(WMSI)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Coronary artery disease" id="2739"><Endpoint>Assessment of Global/Regional Myocardial Perfusion</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Coronary artery disease" id="2747"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2749">Efficacy/feasibility Assessment</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Coronary artery disease" id="2755"><Endpoint>Assessment of Exercise Capacity/Tolerance</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2758">Maximal CardioPulmonary Exercise Testing (CPET)</SubEndpoint><SubEndpoint disease="Coronary artery disease" id="2761">Six-minute walk test (6MWT)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="6790"><Endpoint>Assessment of Cardiovascular Events</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="688">Angina pectoris</SubEndpoint><SubEndpoint disease="Cardiac failure" id="762">Change in NYHA functional class</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Stem cell transplantation" id="17422"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Stem cell transplantation" id="17431">Assessment by imaging techniques</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Stem cell transplantation" id="17443"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Stem cell transplantation" id="29616">Assessment by minnesota living with heart failure questionnaire(MLHFQ)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Stem cell transplantation" id="17451"><Endpoint>Assessment of Pulmonary Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Stem cell transplantation" id="17460"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Myocardial disease" id="24733"><Endpoint>Assessment of Cardiac Function</Endpoint><SubEndpoints><SubEndpoint disease="Myocardial disease" id="24738">Assessment of left ventricular ejection fraction (LVEF)</SubEndpoint><SubEndpoint disease="Myocardial disease" id="24743">Assessment of myocardial perfusion measures</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Myocardial disease" id="24762"><Endpoint>Assessment of Cardiac Markers</Endpoint><SubEndpoints><SubEndpoint disease="Myocardial disease" id="24763">Assessment of troponin I and /or troponin T levels</SubEndpoint><SubEndpoint disease="Myocardial disease" id="24764">Assessment of BNP or NT-pro-BNP</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Myocardial disease" id="24774"><Endpoint>Assessment of Cardiovascular Events</Endpoint><SubEndpoints><SubEndpoint disease="Myocardial disease" id="24776">Change in NYHA functional class</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Myocardial disease" id="24789"><Endpoint>Assessment of Non Cardiovascular  Events</Endpoint><SubEndpoints><SubEndpoint disease="Myocardial disease" id="24794">Assessment of pulmonary functions or events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Myocardial disease" id="24799"><Endpoint>Assessment of Exercise Capacity/Tolerance</Endpoint><SubEndpoints><SubEndpoint disease="Myocardial disease" id="24802">Six-minute walk test (6MWT)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Myocardial disease" id="24812"><Endpoint>Assessment of Device Related Endpoints</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Coronary artery disease" id="26218"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="26230">Minnesota living with heart failure questionnaire</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Myocardial disease" id="26740"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Myocardial disease" id="26747">Minnesota living with heart failure (MLHF) score</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="28679"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="28689">Minnesota living with heart failure(MLWHF) questionnaire</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Cardiac failure" id="282"><Criterion>Subjects with Ventricular Structural/Functional Abnormality</Criterion></Inclusion><Inclusion disease="Cardiac failure" id="290"><Criterion>Subjects with Poor Ejection Fraction</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="292">LVEF = or &lt; 35% (Poor global contractile function)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cardiac failure" id="297"><Criterion>Subjects with Cardiomyopathy</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="300">Non-ischemic dilated cardiomyopathy (NIDC)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cardiac failure" id="328"><Criterion>Subjects with History of  Ischemic Heart Diseases (IHD)</Criterion></Inclusion><Inclusion disease="Cardiac failure" id="367"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="370">Subjects with history/scheduled to receive beta blockers</SubCriterion><SubCriterion disease="Cardiac failure" id="372">Subjects with history/scheduled to receive angiotensin receptor blockers</SubCriterion><SubCriterion disease="Cardiac failure" id="374">Subjects with history of/scheduled to receive anti-hypertensive medications</SubCriterion><SubCriterion disease="Cardiac failure" id="383">Vasodilators</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cardiac failure" id="402"><Criterion>Subjects with History of/Scheduled for Cardiac Surgery/Intervention</Criterion></Inclusion><Inclusion disease="Cardiac failure" id="912"><Criterion>Subjects co-morbid with cardiovascular disease/disorder</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="338">Arterial hypertension</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1078"><Criterion>Subjects with Myocardial Infarction (MI)</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1084">Prior history of myocardial infarction</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1103"><Criterion>Subjects with disease complications</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1104">Subjects with congestive heart failure</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1127"><Criterion>Subjects with Ability to Perform Protocol Specified Exercise Capacity Tests</Criterion></Inclusion><Inclusion disease="Coronary artery disease" id="1134"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1138">Subjects with history of/scheduled to receive anti-hypertensive medications</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1152"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion></Inclusion><Inclusion disease="Coronary artery disease" id="1180"><Criterion>Subjects with Abnormal ECG/ Echocardiographic Findings</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1181">Left ventricular ejection fraction &gt;25% and &lt;35%</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1201"><Criterion>Coronary Angiogram Findings Suggestive of/Confirmed CAD/CHD</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1223">Stenosis or lesion of one major epicardial artery</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stem cell transplantation" id="17877"><Criterion>Subjects with Systemic Disorders Indicated for SCT</Criterion><SubCriteria><SubCriterion disease="Stem cell transplantation" id="17879">Subjects with cardiovascular diseases/disorders indicated for SCT</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Stem cell transplantation" id="17927"><Criterion>Subjects with Normal/Acceptable Laboratory Criteria</Criterion></Inclusion><Inclusion disease="Myocardial disease" id="21365"><Criterion>Subjects with Dilated Cardiomyopathy</Criterion><SubCriteria><SubCriterion disease="Myocardial disease" id="21371">Ischemic cardiomyopathy subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myocardial disease" id="21394"><Criterion>Inclusion of Subjects Based on NYHA Class</Criterion><SubCriteria><SubCriterion disease="Myocardial disease" id="21397">Subjects with heart failure, NYHA class III</SubCriterion><SubCriterion disease="Myocardial disease" id="21398">Subjects with heart failure, NYHA class IV</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myocardial disease" id="21415"><Criterion>Subjects co-morbid with cardiovascular disease/disorder</Criterion><SubCriteria><SubCriterion disease="Myocardial disease" id="21417">Subjects with myocardial infarction</SubCriterion><SubCriterion disease="Myocardial disease" id="21421">Subjects co-morbid with coronary artery disease</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myocardial disease" id="21416"><Criterion>Subjects co-morbid with heart failure</Criterion></Inclusion><Inclusion disease="Cardiac failure" id="31870"><Criterion>Inclusion of Subjects Based on NYHA Class</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="276">Subjects with heart failure, NYHA class III</SubCriterion><SubCriterion disease="Cardiac failure" id="277">Subjects with heart failure, NYHA class IV</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myocardial disease" id="33306"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Myocardial disease" id="21392">Subjects with acceptable left ventricular ejection fraction(LVEF)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myocardial disease" id="33609"><Criterion>Subjects with Acceptable Vital Signs</Criterion><SubCriteria><SubCriterion disease="Myocardial disease" id="21452">Subjects with normal/acceptable blood pressure</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="34202"><Criterion>Subjects co-morbid with cardiovascular disease/disorder</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1123">Subjects co-morbid with cardiomyopathy</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Cardiac failure" id="448"><Criterion>Subjects co-morbid with Arrhythmias/Conduction Disorders</Criterion></Exclusion><Exclusion disease="Cardiac failure" id="456"><Criterion>Subjects with Valvular Heart Diseases</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="459">Valvular stenosis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="469"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Cardiac failure" id="481"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="484">Subjects with CABG (Coronary artery bypass graft) surgery</SubCriterion><SubCriterion disease="Cardiac failure" id="485">Subjects with implanted/scheduled to receive pacemakers/device</SubCriterion><SubCriterion disease="Cardiac failure" id="486">Subjects with history of/schdeuled for percutaneous transluminal coronary angioplasty (PTCA)</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="503"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="506">Anticoagulants</SubCriterion><SubCriterion disease="Cardiac failure" id="507">Antiplatelet agent</SubCriterion><SubCriterion disease="Cardiac failure" id="514">Subjects with history of/scheduled to receive corticosteroids</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="525"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="536">Cytostatics/Cytotoxic drug therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="543"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Cardiac failure" id="605"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Cardiac failure" id="640"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="642">Subjects co-morbid with hepatitis B virus infection</SubCriterion><SubCriterion disease="Cardiac failure" id="643">Subjects co-morbid with hepatitis C virus infection</SubCriterion><SubCriterion disease="Cardiac failure" id="644">Subjects co-morbid with HIV infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="647"><Criterion>Obese Subjects</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="648">Morbid obesity (Grade 3 obesity, BMI=40 kg/square meter)</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="1387"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="742">Subjects with Hypersensitivity/Contraindication to MRI</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1602"><Criterion>Subjects with Myocardial Infarction (MI)</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="1638"><Criterion>Subjects with Valvular Heart Diseases</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1639">Aortic /mitral valve replacement</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1651"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1643">Subjects co-morbid with aortic stenosis</SubCriterion><SubCriterion disease="Coronary artery disease" id="1665">Left ventricular hypertrophy or dysfunction(clinical/ECG/echo/CXR)</SubCriterion><SubCriterion disease="Coronary artery disease" id="1666">Left ventricular thrombus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1668"><Criterion>Subjects co-morbid with Arrhythmias/Conduction Disorders</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1678">Subjects co-morbid with ventricular arrhythmia/fibrillation</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1680"><Criterion>Subjects with Angina/Chest Pain</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="1696"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="1775"><Criterion>Subjects with vascular complications</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1776">Subjects with aneurysm as a complication</SubCriterion><SubCriterion disease="Coronary artery disease" id="1777">Subjects with aortic dissection as a complication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1780"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="5587">Subjects co-morbid with respiratory disorders/disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1842"><Criterion>Subjects with History of/Scheduled for Diagnostic/Therapeutic Procedures</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="1880"><Criterion>Subjects with Hypersensitivity/Contraindication to Therapy</Criterion></Exclusion><Exclusion disease="Stem cell transplantation" id="15718"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Stem cell transplantation" id="15839"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Myocardial disease" id="19163"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Myocardial disease" id="19167">Subjects co-morbid with coronary artery disease</SubCriterion><SubCriterion disease="Myocardial disease" id="19169">Subjects co-morbid with stable/unstable angina</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myocardial disease" id="19166"><Criterion>Subjects co-morbid with Arrhythmias/Conduction Disorders</Criterion></Exclusion><Exclusion disease="Myocardial disease" id="19170"><Criterion>Subjects with history of cardiac surgery/intervention</Criterion></Exclusion><Exclusion disease="Myocardial disease" id="19176"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion><SubCriteria><SubCriterion disease="Myocardial disease" id="19177">Subjects on dialysis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myocardial disease" id="19179"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion><SubCriteria><SubCriterion disease="Myocardial disease" id="19181">Cognitive impairment/mentally ill</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myocardial disease" id="19188"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Myocardial disease" id="19196"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Myocardial disease" id="19197">Subjects with tumors or malignancy</SubCriterion><SubCriterion disease="Myocardial disease" id="19208">Subjects co-morbid with diabetic complications</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myocardial disease" id="19204"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Myocardial disease" id="19205">Subjects co-morbid with HIV infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myocardial disease" id="19210"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Myocardial disease" id="19212">Hypersensitivity/contraindications to any food constituents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myocardial disease" id="19217"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion><SubCriteria><SubCriterion disease="Myocardial disease" id="19218">Subjects with a history/current use of protocol prohibited glucorticoid/steroid</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myocardial disease" id="25738"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Myocardial disease" id="19185">Pregnant/lactating women</SubCriterion><SubCriterion disease="Myocardial disease" id="19186">Positive serum/urine pregnancy test</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="25834"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1701">Subjects on hemodialysis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="25881"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="671">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="26014"><Criterion>Subjects with Angina/Chest Pain</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="447">Subjects with unstable angina</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="26158"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1805">Anticoagulant therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myocardial disease" id="26987"><Criterion>Subjects co-morbid with heart disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Myocardial disease" id="19171">Subjects co-morbid with valvular heart diseases</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="27043"><Criterion>Subjects with history of cardiovascular disease/disorder</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="441">Subjects with history of myocardial infarction</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="27060"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="572">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myocardial disease" id="27078"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Myocardial disease" id="19199">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2013-01-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2011-01-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>13.03 Months</EnrollmentPeriod><EnrollmentRate>1.69 Patients/Month</EnrollmentRate><DateFirstReceived>2009-11-25T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-12-31T07:05:38Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-06-03T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2014-09-04T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="79125"><TitleDisplay>A Study of the Pharmacokinetics and Safety of MK-8808</TitleDisplay><TitleOfficial>A Two-Part, Phase I, Randomized, Double-Blind, Active-Comparator Controlled, Parallel-Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of MK-8808 and to Compare the Pharmacokinetics of MK-8808 With  EU-approved MabThera and US-Licensed Rituxan in Patients With Rheumatoid Arthritis (RA)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01390441</Identifier><Identifier type="Organisational Study">8808-002</Identifier><Identifier type="Other">MK-8808-002 AM3 EXT 1</Identifier><Identifier type="Other">MK-8808 002</Identifier></Identifiers><Indications><Indication id="291">Rheumatoid arthritis</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="781" role="Therapeutic effect marker" type="Physiological">Erythrocyte sedimentation rate</BiomarkerName><BiomarkerName id="3451" role="Therapeutic effect marker" type="Genomic;Proteomic">Immunoglobulin G</BiomarkerName><BiomarkerName id="30214" role="Therapeutic effect marker" type="Physiological;Structural (imaging)">Joint swelling</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>methotrexate</Name></Intervention><Intervention type="InterventionPrimary"><Name>rituximab biosimilar, Merck &amp; Co</Name><Drug id="71923">rituximab biosimilar, Merck &amp; Co</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="duo"><Interventions><Intervention type="InterventionControl"><Name>methotrexate</Name></Intervention><Intervention type="InterventionControl"><Name>rituximab biosimilar, Merck &amp; Co</Name><Drug id="71923">rituximab biosimilar, Merck &amp; Co</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="71923">rituximab biosimilar, Merck &amp; Co</Drug><IndicationsPioneer><Indication id="291">Rheumatoid arthritis</Indication></IndicationsPioneer><Companies><Company><Company id="1059823">Merck Sharp &amp; Dohme Corp</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company><Company><Company id="1089865">PAREXEL International (Singapore) Pte Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="71923" type="Drug"><TargetEntity id="743398" type="siDrug">MK-8808</TargetEntity></SourceEntity><SourceEntity id="1059823" type="Company"><TargetEntity id="4295904507" type="organizationId">Merck Sharp &amp; Dohme Corp</TargetEntity></SourceEntity><SourceEntity id="1089865" type="Company"><TargetEntity id="5000100416" type="organizationId">PAREXEL International (Singapore) Pte Ltd</TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="6">Terminated</RecruitmentStatus><NumberOfSites>5</NumberOfSites><CompaniesSponsor><Company id="1059823">Merck Sharp &amp; Dohme Corp</Company><Company id="1089865">PAREXEL International (Singapore) Pte Ltd</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2953">Anti-inflammatory</Class><Class id="55685">Anticancer monoclonal antibody</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="962">Biosimilar product</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="51">Monoclonal antibody</Technology><Technology id="85">Protein recombinant</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>100</PatientCountEnrollment><DateStart>2011-07-31T00:00:00Z</DateStart><DateEnd type="actual">2014-04-30T00:00:00Z</DateEnd><DateChangeLast>2019-01-26T04:23:10Z</DateChangeLast><DateAdded>2011-07-25T05:46:34Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Changi General Hospital</Affiliation><Name>Dr Yoon Kam Hon</Name></Contact><Contact type="Scientific contact"><Affiliation>Merck Sharp &amp; Dohme Corp.</Affiliation><Name>Medical Director</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Female participants of reproductive potential must demonstrate a serum beta-human chorionic gonadotropin (hCG) level consistent with the nongravid state at the pre-study (screening) visit, and a negative urine pregnancy test within 24 h prior to all doses and agree to use (and/or have their partner use) two acceptable methods of birth control beginning at least 2 weeks prior to administration of the first dose of study drug, throughout the study (including washout intervals between treatment periods/panels) and until at least 12 months after administration of the last dose of study drug in the last treatment period&lt;/li&gt;&lt;li&gt;The participant has a Body Mass Index (BMI)&amp;lt;/= 35 kg/m2 at the prestudy (screening) visit&lt;/li&gt;&lt;li&gt;For part A only: the participant has a body surface are (BSA)&amp;lt;/= 2.0 m2 at the prestudy (screening) visit&lt;ul&gt;&lt;li&gt;Has satisfied at least 4 of 7 American Rheumatology Association (ARA) 1987 revised criteria for the diagnosis of RA&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Is American College of Rheumatology (ACR) Functional Class I, II, or III&lt;/li&gt;&lt;li&gt;Had a diagnosis of RA made at least 6 months prior to the prestudy (screening) visit, was &gt;/= 16 years of age when diagnosed, and has active disease&lt;/li&gt;&lt;li&gt;Is on a stable oral, IM, or SC dose of methotrexate and is continuing to take methotrexate&lt;/li&gt;&lt;li&gt;Has an inadequate response or intolerance to at least one disease-modifying antirheumatic drug (DMARD)&lt;/li&gt;&lt;li&gt;For part A: participant is either naïve to biological therapy for RA or has had an inadequate response to previous or current treatment with an anti-tumor necrosis factor (TNF) treatment (patient could have failed up to three anti-TNF agents treatments) or participant has had intolerance up to three anti-TNF treatments&lt;/li&gt;&lt;li&gt;For part B: participant has had an inadequate response to previous or current treatment with an anti-TNF treatment (patient could have failed up to three anti-TNF agents treatments) or participant has had intolerance up to three anti-TNF treatments&lt;/li&gt;&lt;li&gt;Participant has no clinically significant abnormality on electrocardiogram performed at the prestudy (screening) visit and/or prior to administration of the initial dose of study drug&lt;/li&gt;&lt;li&gt;For part B only: participant is positive for rheumatoid factor (RF) or, if negative for RF, is positive for anti-CCP at screening visit&lt;/li&gt;&lt;li&gt;For part C only: participant must have completed the first 52 weeks of treatment in the base study&lt;/li&gt;&lt;li&gt;For part C only: participant achieved a minimum 20% response from baseline on the American College of Rheumatology (ACR) Responder Index (ACR20) at visit 19 (last visit for the base study)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Mentally or legally incapacitated, has significant emotional problems at the time of the prestudy (screening) visit or during the conduct of the study or has a history of a clinically significant psychiatric disorder over the last five years&lt;/li&gt;&lt;li&gt;Creatinine clearance of&amp;lt;/= 80 m/min&lt;/li&gt;&lt;li&gt;History of stroke, chronic seizures or major neurological disorder&lt;/li&gt;&lt;li&gt;History of neoplastic disease, except treated basal cell carcinoma or carcinoma in situ of the cervix or other malignancies which have been successfully treated &gt;/= 5 years&lt;/li&gt;&lt;li&gt;History of leukemia, lymphoma, malignant melanoma, or myeloproliferative disease regardless of the time since treatment&lt;/li&gt;&lt;li&gt;History of coronary artery disease, congestive heart failure (New York Heart Association Class I-IV), or a history of clinically significant arrhythmia (including any history of atrial fibrillation, atrial flutter, or any sustained ventricular arrhythmia)&lt;/li&gt;&lt;li&gt;Hypersensitivity or allergy to rituximab or any of the excipients of MK-8808 or rituximab (MabThera or Rituxan )&lt;/li&gt;&lt;li&gt;History of a rheumatic autoimmune disease other than RA (eg, systemic lupus erythematosus (SLE), polymyositis, etc)&lt;/li&gt;&lt;li&gt;Severe active infection of any type or history of a medically serious infection as defined by a history of treatment requiring hospitalization, long term IV outpatient treatment for systemic bacterial, viral or fungal infection, use of IV antibiotics within 30-days of screening, or use of antibiotic therapy three or more times in the last 6 months prior to screening&lt;/li&gt;&lt;li&gt;History of opportunistic infection&lt;/li&gt;&lt;li&gt;Active-virus vaccination within 4 weeks&lt;/li&gt;&lt;li&gt;Active tuberculosis with or without adequate treatment, history of latent tuberculosis without written confirmation from health care provider of adequate prophylaxis or any evidence of tuberculosis on a chest X-ray performed within 3 months of dosing&lt;/li&gt;&lt;li&gt;Chronic hepatitis B or hepatitis C infection or has human immunodeficiency virus (HIV) infection&lt;/li&gt;&lt;li&gt;Previously treated with rituximab (MabThera or Rituxan) or any investigational anti-CD20 antibody&lt;/li&gt;&lt;li&gt;Active use or planned use of a prohibited DMARD during the course of study participation, and/or insufficient washout from a prohibited DMARD at the time of the planned first dose of MK-8808/rituximab (MabThera or Rituxan)&lt;/li&gt;&lt;li&gt;Had major surgery, donated or lost 1 unit of blood (approximately 500 ml) within 4 weeks&lt;/li&gt;&lt;li&gt;Participated in another investigational study with length of time within at least five half-lives of the previous investigational study drug&lt;/li&gt;&lt;li&gt;Pregnant or breastfeeding or expecting to conceive&lt;/li&gt;&lt;li&gt;Allergy to murine proteins&lt;/li&gt;&lt;li&gt;Allergy or sensitivity to components of the drug vial or any of the materials used for infusion&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Part A: area under the concentration-time curve from days 0 to 84 (AUC 0 to 84 day) After a Single course of treatment: AUC is a measure of the amount of drug in the plasma over time; samples are collected at intervals from pre-dose up to 84 days after the dose. Descriptive data values and associated dispersion measures (confidence intervals) are expressed in terms of the factor 10E6</Description><Timeframe>Days 1 (pre- and post-dose), 3, 5, 8, 15, 17, 19, 22, 29, 43, 57, and 85</Timeframe></Measure><Measure><Description>Part B: area under the concentration-time curve from days 0 to 84 (AUC 0 to 84 day) after a single course of treatment: AUC is a measure of the amount of drug in the plasma over time; samples are collected at intervals from pre-dose up to 84 days after the dose</Description><Timeframe>Days 1 (pre- and post-dose), 3, 5, 8, 15, 17, 19, 22, 29, 43, 57, and 85</Timeframe></Measure><Measure><Description>Number of participants who experienced at least one adverse event: an adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure</Description><Timeframe>Parts A and B: up to 52 weeks; extension A and B: up to 106 weeks</Timeframe></Measure><Measure><Description>Number of participants who discontinued study drug due to adverse events: discontinuation/withdrawal of study treatment due to an adverse event was performed at the discretion of the investigator or the Sponsor for safety concerns. An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure</Description><Timeframe>Parts A and B: up to week 28; extension A and B: up to 82 weeks</Timeframe></Measure><Measure><Description>Number of participants with Immunoglobulin G (IgG) Response in the extension study: Serum IgG levels are determined over course of therapy with MK-8808 in the extension study</Description><Timeframe>Weeks 54, 68, 80, 94, and 106</Timeframe></Measure><Measure><Description>Number of participants positive for Anti-Drug Antibody (ADA) Formation in the extension study: serum ADA positivity is determined over course of therapy with MK-8808 in the extension study.</Description><Timeframe>Weeks 54, 56, 68, 80, 82, 94, and 106</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Part A: maximum concentration (Cmax) after the second infusion of a single course of treatment: Cmax is a measure of the maximum plasma concentration of drug; samples are collected on day 15 after the second infusion of the first course of treatment. Descriptive data values and associated dispersion measures (confidence intervals) are expressed in terms of the factor 10E3</Description><Timeframe>Day 15</Timeframe></Measure><Measure><Description>Part B: Cmax after the second infusion of a single course of treatment: Cmax is a measure of the maximum plasma concentration of drug; samples are collected on day 15 after the second infusion of the first course of treatment</Description><Timeframe>Day 15</Timeframe></Measure><Measure><Description>Part A: number of ACR20, ACR50, and ACR70 responders at week 24: American College of Rheumatology (ACR) Responder Index is based on a set of evaluations: the Investigator Tender Joint Count/Number of Tender Joints (out of 68 Joints); Investigator Swollen Joint Count/Number of Swollen Joints (out of 66 Joints); Patient Global Assessment of Disease Activity (PGAD); Investigator Global Assessment of Disease Activity (IGAD); Patient Global Assessment of Pain (PGAP); HAQ-D; and ESR. ACR response indicates percent change (ie, improvement) from baseline (20, 50, and 70%) PGAD and IGAD: assessment of function on a 4-point Likert scale: 0 = very well to 3 = unable to do PGAP: pain due to arthritis measured on a 0 to 100 mm visual analog scale: left hand marker- no pain; right hand marker- extreme pain HAQ-DI: assessment of 8 daily living activities (dress/groom; arise; eat; walk; reach; grip; hygiene; common daily activities) on four-point Likert scale: 0 = no difficulty to 3 = unable to do</Description><Timeframe>Week 24</Timeframe></Measure><Measure><Description>Part B: number of ACR20, ACR50, and ACR70 responders at week 24: American College of Rheumatology (ACR) Responder Index is based on a set of evaluations: the Investigator Tender Joint Count/Number of Tender Joints (out of 68 Joints); Investigator Swollen Joint Count/Number of Swollen Joints (out of 66 Joints); Patient Global Assessment of Disease Activity (PGAD); Investigator Global Assessment of Disease Activity (IGAD); Patient Global Assessment of Pain (PGAP); HAQ-D; and ESR. ACR response indicates percent change (ie, improvement) from baseline (20, 50, and 70%) PGAD and IGAD: assessment of function on a 4-point Likert scale: 0 = very well to 3 = unable to do PGAP: pain due to arthritis measured on a 0 to 100 mm visual analog scale: left hand marker- no pain; right hand marker- extreme pain HAQ-DI: assessment of 8 daily living activities (dress/groom; arise; eat; walk; reach; grip; hygiene; common daily activities) on four-point Likert scale: 0 = no difficulty to 3 = unable to do</Description><Timeframe>Week 24</Timeframe></Measure><Measure><Description>Change from baseline in disease activity in 28 joints C-Reactive Protein Score (DAS28-CRP) by Time-point: the DAS28-CRP is a combination scoring method for function using the European League against Rheumatism (EULAR) 28 joint count and the CRP value. The DAS28-CRP scores range from 2.0 to 10.0 with higher values indicating a higher disease activity. A DAS28-CRP below the score of 2.6 is interpreted as Remission. CRP values below lower limit of quantification (LLQ) (&lt; 0.4 mg/dl) were set to 0.2 mg/dl in the calculation of DAS28-CRP</Description><Timeframe>Baseline, weeks 6 and 12</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This was a study of the overall safety, tolerability, and pharmacokinetics (PK) of &lt;ulink linkType="Drug" linkID="71923"&gt;MK-8808&lt;/ulink&gt; in
      comparison with &lt;ulink linkType="Drug" linkID="6736"&gt;rituximab&lt;/ulink&gt; (&lt;ulink linkType="Drug" linkID="6736"&gt;MabThera&lt;/ulink&gt;) in patients with moderate to severe rheumatoid arthritis
      (RA) with an inadequate response or intolerance to methotrexate.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Study consist of two parts:&lt;br/&gt;Part A: MK-8808 500 mg/m2/extension A: MK-8808 1000 mg: during the treatment period, patients receive one course of MK-8808 (500 mg/m2) administered iv on  days 1 and 15 (with a second optional course of treatment with 1000 mg at weeks 26 and 28). Patients would be followed up to week 52 in the treatment period. During the extension period, patients receive open-label MK-8808 (1000 mg) administered iv at weeks 54 and 56 (with a second optional course at weeks 80 and 82). Patients would be followed up to week 106 in the extension period. &lt;br/&gt;Part A: MabThera 500 mg/m2/extension A: MK-8808 1000 mg: during the treatment period, patients receive one course of MabThera (500 mg/m2) administered iv on  days 1 and 15 (with a second optional course of treatment at weeks 26 and 28). Patients would be followed up to week 52 in the treatment period. During the extension period, patients receive open label MK-8808 (1000 mg) administered  iv at weeks 54 and 56 (with a second optional course at weeks 80 and 82). Patients would be followed up to week 106 in the extension period. &lt;/para&gt;&lt;para&gt;Part B: MK-8808 1000 mg/extension B: MK-8808 1000 mg: in the treatment period, patients receive one course of  MK-8808 (1000 mg) administered iv on days 1 and 15 (with a second optional course of treatment at weeks 26 and 28). Patients would be followed up to week 52 in the treatment period. In the extension period, patients receive open-label MK-8808 (1000 mg) adminstered iv at weeks 54 and 56 (with a second optional course at weeks 80 and 82). Patients would be followed up to week 106 in the extension period. &lt;br/&gt;Part B: MabThera 1000 mg/extension B: MK-8808 1000 mg: in the treatment period, patients receive one course of  MabThera (1000 mg) administered iv on days 1 and 15 (with a second optional course of treatment at weeks 26 and 28). Patients would be followed up to week 52 in the treatment period. In the extension period, patients receive open-label MK-8808 (1000 mg) administered iv at week 54 and  56 (with a second optional course atweeks 80 and 82). Patients would be followed up to week 106 in the extension period. &lt;/para&gt;&lt;para&gt;Methotrexate 12.5 to 25 mg/week would be administered either po, sc, or im for the duration of the trial. A 10 mg dose might be administered if a greater dose would not be tolerated. Methylprednisolone 100 mg administered iv before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions. Acetaminophen 1000 to 1350 mg administered po before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions. Loratidine 10 mg administered po before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions.&lt;br/&gt;&lt;br/&gt;The extension portion of the study (part C) would sequentially follow the base study beginning at week 52 and continue for an additional 54 weeks. All patients who meet eligibility criteria and continue into the study extension would be treated with open-label &lt;ulink linkType="Drug" linkID="71923"&gt;MK-8808&lt;/ulink&gt;. Patients randomized to &lt;ulink linkType="Drug" linkID="71923"&gt;MK-8808&lt;/ulink&gt; in the base study would remain on the same therapy. Patients randomized to rituximab (&lt;ulink linkType="Drug" linkID="6736"&gt;MabThera&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="6736"&gt;Rituxan&lt;/ulink&gt;) in the base study would be switched to &lt;ulink linkType="Drug" linkID="71923"&gt;MK-8808&lt;/ulink&gt; for the extension study.&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;The study was terminated early by the sponsor for business reasons.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Russian Federation"><Sites><Site><Name>Public health agency 'Sverdlovsk Regional Clinical Hospital No 1'</Name><Address1>Moscow</Address1><Address3>620102</Address3><Contacts></Contacts></Site><Site><Name>State Health Care Institution 'Republican Hospital. V. Baranov,'the Ministry of Health of the Republic of Karelia'</Name><Address1>Petrozavodsk</Address1><Address3>185000</Address3><Contacts></Contacts></Site><Site><Name>FKUZ 'Health part of the Ministry of Internal Affairs of the Russian Federation in Moscow'</Name><Address1>Moscow</Address1><Address3>127994</Address3><Contacts></Contacts></Site><Site><Name>Municipal autonomous institution 'City Clinical Hospital no 40'</Name><Address1>Ekaterinburg</Address1><Address3>620102</Address3><Contacts></Contacts></Site><Site><Name>Limited Liability Company 'Research Medical Complex'</Name><Address1>Kazan</Address1><Address3>420097</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Rheumatoid arthritis</Disease><PatientSegments><PatientSegment><PatientSegment id="502">Active Rheumatoid Arthritis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="513">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="514">Treatment Naive Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="537">Subjects on Rheumatoid Arthritis Therapy</PatientSegment><SubSegments><SubSegment id="538">Methotrexate</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01390441</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier></Identifier></Identifiers></Registry><Registry><Name id="1030">Russian State Register of Medicines Clinical Trials Registry</Name><Identifiers><Identifier></Identifier></Identifiers></Registry><Registry><Name id="1035">Singapore Health Services Authority Clinical Trials Registry
</Name><Identifiers><Identifier></Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Rheumatoid arthritis" id="4144"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Rheumatoid arthritis" id="6891"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Rheumatoid arthritis" id="4144"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Rheumatoid arthritis" id="6891"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Rheumatoid arthritis" id="1900"><Criterion>Active Rheumatoid Arthritis</Criterion></Inclusion><Inclusion disease="Rheumatoid arthritis" id="1914"><Criterion>ACR Functional Status Classification for Rheumatoid Arthritis</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="1915">ACR functional class I</SubCriterion><SubCriterion disease="Rheumatoid arthritis" id="1916">ACR functional class II</SubCriterion><SubCriterion disease="Rheumatoid arthritis" id="1917">ACR functional class III</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Rheumatoid arthritis" id="1931"><Criterion>Subjects on Rheumatoid Arthritis Therapy</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="1932">Subjects on methotrexate (MTX)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Rheumatoid arthritis" id="1940"><Criterion>Subjects with Treatment Resistant Disease</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="1942">Subjects with biological DMARD resistant/refractory disease</SubCriterion><SubCriterion disease="Rheumatoid arthritis" id="2001">Subjects with DMARD refractory/resistant disease</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Rheumatoid arthritis" id="1945"><Criterion>Treatment Naive Subjects</Criterion></Inclusion><Inclusion disease="Rheumatoid arthritis" id="1969"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="1938">Subjects receiving/scheduled to receive stable medication</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Rheumatoid arthritis" id="2022"><Criterion>Subjects with Contra-indications to Rheumatoid Arthritis Medications</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2023">Contra-indications to TNF-alpha inhibitor</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Rheumatoid arthritis" id="2820"><Criterion>Subjects with Autoimmune/Immunological Disorders</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2836"><Criterion>Subjects co-morbid with musculoskeletal diseases/disorders</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2845"><Criterion>Subjects with History of Use of Rheumatoid Arthritis Therapy</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2846">Subjects with history of biological DMARDs</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2867"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2868">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2870"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2871">Subjects co-morbid with coronary artery disease</SubCriterion><SubCriterion disease="Rheumatoid arthritis" id="2873">Subjects co-morbid with congestive heart failure (NYHA Class III and Class IV)</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2875"><Criterion>Subjects co-morbid with Arrhythmias/Conduction Disorders</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2879"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2885"><Criterion>Subjects co-morbid with CNS disorders</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2898"><Criterion>Subjects co-morbid with Hepatic Disorders/Diseases</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2901">Hepatitis B/Hepatitis C</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2906"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2833">Subjects with systemic lupus erythematosus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2910"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2915"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2916">Lymphoproliferative diseases</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2919"><Criterion>Subjects with Immunodeficiency Disorders</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2921">HIV positive/AIDS subjects</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2922"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2923">Subjects co-morbid with tuberculosis</SubCriterion><SubCriterion disease="Rheumatoid arthritis" id="2924">Subjects co-morbid with bacterial infections</SubCriterion><SubCriterion disease="Rheumatoid arthritis" id="2926">Subjects co-morbid with viral infection</SubCriterion><SubCriterion disease="Rheumatoid arthritis" id="2927">Subjects with history of / current fungal infections</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2929"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Rheumatoid arthritis" id="2931"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2932">Vaccination</SubCriterion><SubCriterion disease="Rheumatoid arthritis" id="2987">Subjects with history of antibiotics for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="25800"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2981">Subjects with history of DMARDs</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="27021"><Criterion>Subjects co-morbid with Cerebrovascular Disorders/Diseases</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2888">Subjects co-morbid with stroke</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Rheumatoid arthritis" id="27143"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Rheumatoid arthritis" id="2944">Protocol Specified Other Laboratory Findings for Exclusion</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2014-04-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2011-07-07T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2011-07-25T05:46:34Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-05-13T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2016-07-29T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="82735"><TitleDisplay>A Study to Evaluate Chitosan Chewing Gum in Patients With Chronic Kidney Disease</TitleDisplay><TitleOfficial>A Multicenter, Open-Label Study to Evaluate Chitosan Chewing Gum in Patients With Chronic Kidney Disease</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">CMD007</Identifier><Identifier type="NCT">NCT01475760</Identifier></Identifiers><Indications><Indication id="1003">Hyperphosphatemia</Indication></Indications><BiomarkerNames><BiomarkerName id="2382" role="Therapeutic effect marker" type="Biochemical">Phosphorus</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Fostrap</Name><Drug id="70258">Fostrap</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="70258">Fostrap</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="1049304">CM&amp;D Pharma Ltd</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company><Company><Company id="1060639">Denver Nephrology</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1049304" type="Company"><TargetEntity id="5001450257" type="organizationId">CM &amp; D Pharma Ltd</TargetEntity></SourceEntity><SourceEntity id="1060639" type="Company"><TargetEntity id="5011670572" type="organizationId">Denver Nephrology</TargetEntity></SourceEntity><SourceEntity id="1003" type="ciIndication"><TargetEntity id="10020711" type="MEDDRA"></TargetEntity><TargetEntity id="D054559" type="MeSH"></TargetEntity><TargetEntity id="-503652923" type="omicsDisease"></TargetEntity><TargetEntity id="1000" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>4</NumberOfSites><CompaniesSponsor><Company id="1060639">Denver Nephrology</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1049304">CM&amp;D Pharma Ltd</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="1467">Renal system agent</Class><Class id="472">Phosphate lowering agent</Class></Class><Technologies><Technology id="680">Buccal formulation systemic</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>167</PatientCountEnrollment><DateStart>2011-11-30T00:00:00Z</DateStart><DateEnd type="actual">2012-03-31T00:00:00Z</DateEnd><DateChangeLast>2018-07-24T04:53:37Z</DateChangeLast><DateAdded>2011-12-01T06:44:14Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>DenverNephrologists, P.C.</Affiliation><Name>Geoffrey Block, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Men or women&amp;gt; 18 years of age&lt;/li&gt;&lt;li&gt;The subject has voluntarily signed and dated the most recent informed consent form
             approved by   an Institutional Review Board (IRB)&lt;/li&gt;&lt;li&gt;The subject will, in the opinion of the investigator, be compliant with prescribed
             therapy and all study visits&lt;/li&gt;&lt;li&gt;Subject must be able to communicate and be able to understand and comply with the
             requirements of the study&lt;/li&gt;&lt;li&gt;For subjects not on dialysis estimated glomerular filtration rate (GFR)  at screening&amp;lt;/= 60 ml/min + 10% that in the opinion of the investigator is stable and not expected to initiate
             dialysis within 3 months&lt;/li&gt;&lt;li&gt;Subject must have serum phosphorus at screening of &gt;/=  3.5
             mg/dl&lt;/li&gt;&lt;li&gt;Subjects must have a screening salivary flow rate by Saxon test &gt;/= 1 g/2 min&lt;/li&gt;&lt;li&gt;All subjects must have no change in prescribed dose or frequency of any of the
             following medications &gt;/= 14 days prior to run-in visit 2 (day  -15):&lt;ul&gt;&lt;li&gt;Phosphate binding products including prescribed and over-the counter&lt;/li&gt;&lt;li&gt;Oral or
        injectable active vitamin D&lt;/li&gt;&lt;li&gt;Oral nutritional vitamin D&lt;/li&gt;&lt;li&gt;Calcium supplements&lt;/li&gt;&lt;li&gt;Anti-osteoporotic medication (eg, bisphosphonates)&lt;/li&gt;&lt;li&gt;Cinacalcet&lt;/li&gt;&lt;li&gt;Subject must be
       prescribed a diet appropriate for patients with their stage of CKD, must be willing to
        avoid intentional changes in diet and must have stable nutritional status in the opinion
        of the investigator&lt;/li&gt;&lt;li&gt;Subjects on dialysis must, in the opinion of the investigator, have a stable dialysis
        prescription, stable dialysis access and a URR&amp;gt;/= 65% for at least 4 weeks prior to day
        -15&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Subject is receiving or has received an investigational product (or is currently
             using an investigational device) within 14 days prior to visit 2 (day -15)&lt;/li&gt;&lt;li&gt;Subject has a known sensitivity to chitin or allergy to shellfish&lt;/li&gt;&lt;li&gt;Subject has had dental work other than cleaning, cavity filling or crown placement
             within 48 h prior to visit 4 (day 1) or at any time during the course of the
             trial&lt;/li&gt;&lt;li&gt;Subject has a clinically significant infection requiring treatment with antibiotics
             (within 7 days prior to visit 2 [day -15])&lt;/li&gt;&lt;li&gt;Subject has had an inpatient hospitalization within 14 days prior to visit 2 (day
             -15) with the exception of hospitalizations related to vascular access procedures&lt;/li&gt;&lt;li&gt;Subject has a known history of immunodeficiency diseases, including a positive HIV
             (ELISA and Western blot) test result&lt;/li&gt;&lt;li&gt;Active drug or alcohol dependence or abuse (excluding tobacco use) in the opinion of
             the principal investigator&lt;/li&gt;&lt;li&gt;In the opinion of the investigator, subject is unable to chew gum for 30 min&lt;/li&gt;&lt;li&gt;Subject has an unstable medical condition which in the opinion of the investigator
             would compromise successful completion of the study&lt;/li&gt;&lt;li&gt;Subject is receiving calcimimetic therapy (acceptable if subject is on dialysis)&lt;/li&gt;&lt;li&gt;Subject has known salivary gland dysfunction or Sjogren's syndrome&lt;/li&gt;&lt;li&gt;Subjects is receiving niacin therapy within 7 days prior to run-in visit 2 (day  -15)
             (use as part of standard multivitamin is acceptable)&lt;/li&gt;&lt;li&gt;Subject has had a major cardiovascular event within 90 days of screening.  The
             investigator should be guided by evidence of any of the following:&lt;ul&gt;&lt;li&gt;Acute myocardial infarction&lt;/li&gt;&lt;li&gt;Acute cerebral vascular event&lt;/li&gt;&lt;li&gt;Vascular surgical
        intervention&lt;/li&gt;&lt;li&gt;Coronary revascularization&lt;/li&gt;&lt;li&gt;Decompensated congestive heart failure&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Serum phosphorus: change in serum phosphorus from baseline to mean of values during 2 weeks active chewing period in patients with CKD not on dialysis</Description><Timeframe>Change from baseline to mean during 2 weeks active therapy</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Serum phosphorus: change in serum phosphorus from baseline to mean of values during active therapy in patients with CKD on dialysis</Description><Timeframe>Change from baseline after 2 weeks active chewing</Timeframe></Measure><Measure><Description>Salivary phosphorus: change in salivary phosphorus from baseline to mean of values during 2 weeks active</Description><Timeframe>Change from baseline to mean during active therapy -2 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study is to determine the efficacy of chitosan chewing gum (K2CG [&lt;ulink linkType="Drug" linkID="70258"&gt;Fostrap&lt;/ulink&gt;]) in
      reducing serum phosphorus in patients with chronic kidney disease (CKD).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This trial is designed to assess 
      the reduction in serum P    for &lt;ulink linkType="Drug" linkID="70258"&gt;Fostrap&lt;/ulink&gt; (strengths/gum sizes [20, 60 mg]; chewing gum formulation) during an open-label phase only in
      those patients who have responded during the primary efficacy assessment phase.  This will
      allow a comparison of efficacy between the two gum sizes/strengths (20, 60 mg) among known 'responders'
      with regard to serum P reduction.&lt;/para&gt;&lt;para&gt;Patients will be randomly assigned in a 1 : 1 fashion to either &lt;ulink linkType="Drug" linkID="70258"&gt;Fostrap&lt;/ulink&gt; chewing gum or standard of care (SOC) if they have a change in serum phosphorus &gt;/= -0.2 mg/dl from baseline (defined as the mean of values from visits 2, 3, and 4) to the end of active treatment (defined as the mean of visits 6 and 7) and/or baseline (defined as the mean of values from visits 2, 3, and 4) and end of washout (defined as visit 7 [day 22]). If randomized, patients will receive either &lt;ulink linkType="Drug" linkID="70258"&gt;Fostrap&lt;/ulink&gt; chewing gum (20 mg chitosan) tid for 14 days beginning on days 1 to 14 or SOC treatments beginning on days 29 to 42.&lt;/para&gt;&lt;para&gt; &lt;/para&gt;&lt;para&gt; &lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Southwest Clinical Reserach Institute, LLC</Name><Address1>Tempe</Address1><Address2>Arizona</Address2><Address3>85284</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Denver Nephrologists, PC</Name><Address1>Denver</Address1><Address2>Colorado</Address2><Address3>80230</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Pacific Renal Research Institute</Name><Address1>Meridian</Address1><Address2>Idaho</Address2><Address3>83642</Address3><CountrySubDivision code="ID">Idaho</CountrySubDivision><Contacts></Contacts></Site><Site><Name>Renal Associates, PA</Name><Address1>San Antonio</Address1><Address2>Texas</Address2><Address3>78215</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>End stage renal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="7703">Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD)</PatientSegment><SubSegments><SubSegment id="7700">Subjects with stage 3 chronic kidney disease</SubSegment><SubSegment id="7701">Subjects with stage 4 chronic kidney disease</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="7704">Subjects with Dialysis Dependant Chronic Kidney Disease(DD-CKD)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7717">Subjects with Electrolyte Imbalance/Associated Complications</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="20180">Subjects by disease severity</PatientSegment><SubSegments><SubSegment id="7702">Subjects with stage 5 chronic kidney disease/end stage renal disease(ESRD)</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01475760</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="End stage renal disease" id="22549"><Endpoint>Assessment of Serum Electrolytes</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22552">Assessment of phosphate</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="22570"><Endpoint>Assessment of dialysis</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="End stage renal disease" id="22549"><Endpoint>Assessment of Serum Electrolytes</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22552">Assessment of phosphate</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22570"><Endpoint>Assessment of dialysis</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="End stage renal disease" id="17629"><Criterion>Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD)</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17642">Subjects with stage 3 chronic kidney disease</SubCriterion><SubCriterion disease="End stage renal disease" id="17644">Subjects with stage 4 chronic kidney disease</SubCriterion></SubCriteria></Inclusion><Inclusion disease="End stage renal disease" id="17648"><Criterion>Subjects with Dialysis Dependant Chronic Kidney Disease(DD-CKD)</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17652">Subjects with stage 5 CKD/end stage renal disease(ESRD)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="End stage renal disease" id="17678"><Criterion>Subjects with Electrolyte Imbalance/Associated Complications</Criterion></Inclusion><Inclusion disease="End stage renal disease" id="17690"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17696">Subjects on phosphate binders</SubCriterion><SubCriterion disease="End stage renal disease" id="17697">Subjects on nutritional supplements/dietary therapy</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="End stage renal disease" id="17518"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17519"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17531"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17535"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17536"><Criterion>Subjects with History of/Scheduled for Renal Replacement Therapy</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17537">Subjects with protocol specified dialysis related criteria</SubCriterion></SubCriteria></Exclusion><Exclusion disease="End stage renal disease" id="17541"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17548">Subjects with history of/scheduled for nutritional supplements/dietary therapy</SubCriterion><SubCriterion disease="End stage renal disease" id="17550">Subjects with history of/scheduled for antibiotics</SubCriterion></SubCriteria></Exclusion><Exclusion disease="End stage renal disease" id="17551"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17553"><Criterion>Subjects with Contraindications to Study Procedure</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2012-03-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2011-11-17T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2011-12-01T06:44:14Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordsOutput>